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Because getting your dreams 
it's strange, but it seems 
a little - well - complicated. 
There's a kind of a sort of cost, 
there's a couple of things that get lost, 
There are bridges you cross  
you didn't know you crossed 
until you've crossed 
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1. Introduction 
1.1. Pertussis disease 
Pertussis is a highly contagious, acute respiratory disease whose etiological agent is the 
Gram-negative bacterium Bordetella pertussis. The name pertussis takes its origins 
from Latin (per, intensive, and tussis, cough) and describes the most consistent and 
prominent clinical feature of the illness. The common name for the illness, “whooping 
cough”, comes from the characteristic inspiratory sound made at the end of an episode 
of paroxysmal coughing. 
B. pertussis infection results in colonization and rapid multiplication of the bacteria on 
the mucous membrane of the respiratory tract. Histopathological studies of fatal 
pertussis cases documented large airway disease as the principal component of B. 
pertussis infection and showed large numbers of bacteria on cilia lining trachea and 
bronchi, causing local damage (Mallory and Hornor 1912). More recently, electron 
microscopy studies have demonstrated that B. pertussis adheres exclusively to the tufts 
of ciliated epithelial cells of the upper respiratory tract; no attachment to non-ciliated 
cells was observed (Tuomanen and Hendley 1983).  
Transmission 
B. pertussis is a strict human pathogen and no other animal or environmental reservoir 
is known. It is transmitted from human to human through aerosolized respiratory 
droplets expelled via coughing and sneezing, as further demonstrated in a recent study 
in a baboon model (Warfel, Beren et al. 2012). Adults, who often lack classic 
symptoms, have a primary role in the spread of the disease, as they serve as important 
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reservoirs of B. pertussis, transmitting pertussis to infants and children, who are at 
greater risk for morbidity and mortality (Bisgard, Pascual et al. 2004, Wendelboe, 
Njamkepo et al. 2007). 
Clinical manifestations 
Clinical manifestations of the infection may show substantial variation, depending on 
several factors, such as clinical condition and age of the patient, previous vaccination or 
infection, presence of passively acquired antibodies (Mattoo and Cherry 2005). 
Pertussis can result in asymptomatic infection, mild cough illness or classic illness. 
Classic illness often occurs in primary infection in unimmunized children between 1 
and 10 years of age (Cherry 1999), lasts 6 to 12 weeks or longer and is divided into 
three stages: catarrhal, paroxysmal and convalescent phase (Fig.1). After an incubation 
period of 7 to 10 days, illness begins with the catarrhal phase, which lasts 1-2 weeks 
and is usually characterized by nonspecific symptoms including rhinorrhea, lacrimation, 
progressive cough, reduced activity, loss of appetite and occasional low-grade fever. At 
the end of this phase, most children have frequently a leukocytosis with absolute 
lymphocytosis, which is absent in adults (Postels-Multani, Schmitt et al. 1995, Mattoo 
and Cherry 2005, Melvin, Scheller et al. 2014). During the subsequent paroxysmal 
stage, lasting 1-6 weeks or longer, the cough becomes more persistent and severe, with 
paroxysms, consisting of repetitive series of forceful coughs during a single expiration. 
A paroxysm is often followed by a forced inspiration during which the characteristic 
whoop occurs and is often associated with tenacious mucus, cyanosis and post-tussive 
vomiting. The patient usually shows normal airway function between attacks. Infants 
under 6 months of age may not have the strength to have a whoop, so the disease may 
manifest with spells of apnea, with consequent bradycardia, cyanosis and 
unresponsiveness (Christie and Baltimore 1989). The transition to the last convalescent 
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phase is associated with a gradual decrease in the frequency and in the severity of the 
paroxysms before the patient returns to normal. This stage usually lasts 2-3 weeks but it 
is often prolonged. Most of the asymptomatic infections or mild illnesses occur in 
previously immunized or infected subjects, both adolescents and adults. The 
predominant symptom may be a persistent cough, that is often associated with 
nonspecific symptoms of more common viral upper respiratory tract infections (Cornia, 
Hersh et al. 2010). Pertussis is most severe in young infants, but it occurs in all age 
groups. Most deaths due to pertussis occur in infants, for which the infection is 
particularly severe: in neonatal infection the risk of death correlates with frequent 
episodes of apnea, often resulting in seizures due to hypoxia (Christie and Baltimore 
1989), whereas in young infants is related directly with lymphocytosis, which positively 
correlates with intractable pulmonary hypertension, respiratory failure and death 
(Paddock, Sanden et al. 2008).   
1.1.1. Bordetella pertussis 
Bordetella pertussis was first isolated in pure culture by Bordet and Gengou in 1906. It 
is a small (approximately 0.5 x 1 µm) encapsulated bacterium, strict aerobe, non-motile 
and non-sporulating. 
Following the inhalation of infected aerosol, B. pertussis enters the upper respiratory 
tract and adheres to ciliated epithelial cells in the nasopharynx and trachea. Once 
attached to the mucosal surface, B. pertussis produces a wide array of virulence factors, 
including adhesins and toxins. The concerted expression of these factors prevents rapid 
clearance of the bacteria and enables replication and dissemination to the lower areas of 
the respiratory tract (de Gouw, Diavatopoulos et al. 2011). 
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The expression of the majority of these virulence factors is under the control of a two-
component regulatory system encoded by the bvgAS locus (Arico, Miller et al. 1989). 
BvgS is a 135-kDa transmembrane sensor kinase consisting of several domains 
involved in phosphorylation cascade, while BvgA is a 23-kDa response regulator 
protein, with a receiver domain at its N-terminus and a DNA-binding domain at its C-
terminus (Cotter and Jones 2003). Under inducing signals BvgS autophosphorilates and 
initiate a phopshorelay that leads to BvgA phosphorylation and activation (Uhl and 
Miller 1996). Activated BvgA dimerizes and binds to specific DNA sequences to 
positively or negatively regulate transcription (Decker, James et al. 2012). In response 
to environmental conditions, BvgAS controls the expression of at least three distinct 
phenotypic phases, each characterized by maximal expression of some genes and 
minimal expression of others (Lacey 1960). The signals to which BvgS responds in vivo 
are still unknown. Bvg+ phase occurs when bacteria are grown under permissive 
conditions. In this phase BvgAS is active and promotes the expression of virulence-
activated genes (vag-genes, divided in class 1 and class 2 genes), while represses the 
expression of virulence-repressed genes (vrg-genes, or class 4 genes) by the repressor 
protein BvgR, whose gene is located downstream of the bvgAS locus and is activated by 
BvgA (Merkel, Barros et al. 1998). Vag-genes encode adhesins and toxins that play a 
key role in the respiratory tract colonization in vivo (Merkel, Stibitz et al. 1998). Bvg- 
phase occurs when bacteria are grown under modulating conditions, such as growing at 
low temperature (25°C) or in the presence of nicotinic acid or MgSO4 (Melton and 
Weiss 1993). During this phase, BvgAS is inactive and is unable to repress vrg-genes, 
which are therefore maximally expressed, while no expression of vag-genes occurs. 
Since these genes are expressed when bacteria are grown under limiting conditions, they 
may be involved in B. pertussis survival in the ex vivo environment. Bvg
i 
phase occurs 
when bacteria are grown under submodulating conditions (low concentration of 
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chemical modulators). In this phase bacteria display a phenotype that is intermediate 
between Bvg+ phase and Bvg- phase, since BvgAS is partially active: vrg-genes and 
class 1 genes (e.g. PT, ACT) are not expressed, while class 2 genes (e.g. FHA) and the 
genes specific of this phase (class 3 genes) are maximally expressed (Deora, Bootsma et 
al. 2001). This phenotype may be important for transmission between hosts, but this 
remains to be elucidated. The complexity of this system may allow multiple levels of 
control of gene expression that could be important in the infection cycle.   
B. pertussis virulence factors include several adhesins and toxins that contribute to its 
ability to cause the disease. The major virulence factors and antigenic components 
expessed during the virulent Bvg+ phase, are schematically reported in Table 1 and Fig. 
1. Among them, Filamentous hemagglutinin, Pertactin and Pertussis Toxin, are the 
antigens included in three-component acellular pertussis vaccine. 
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Virulence Determinant Description 
    Filamentous hemagglutinin 
   (FHA) 
220 kDa surface-associated and secreted protein. Dominant 
adhesin, promotes attachment to respiratory epithelium. 
Immunomodulatory properties. 
    Pertactin (PRN) 69 kDa outer membrane protein. Autotransporter. Mediates 
eukaryotic cells binding in vitro. Role in resistance to neutrophil-
mediated clearance. 
    Fimbriae (FIM) Filamentous cell surface structures. Two serologic types (type 2 and 
3). Role in mediating adherence to ciliated respiratory epithelium. 
Potential immunomodulatory activity. 
    Pertussis toxin (PT) 105 kDa ADP-ribosylating A-B toxin. Responsible of pertussis-
associated leukocytosis with lymphocytosis, hypoglycemia and 
sensitization to histamine. Important immunomodulatory activity. 
Strong adjuvant. 
    Adenylate cyclase toxin 
   (ACT) 
Calmodulin-activated toxin with adenylate cyclase and hemolysin 
activity. Anti-inflammatory and antiphagocytic factor. Possible 
contribution to local tissue damage in the respiratory tract. 
    Dermonecrotic toxin (DNT) 160 kDa heat-labile cytoplasmic toxin. Activates Rho. Induces 
necrosis in vivo and in vitro. Possible role in bacterial survival and 
local tissue damage in the respiratory tract. 
    Tracheal cytotoxin (TCT) 921 Da disaccharide-tetrapeptide monomer of peptidoglycan. Not 
regulated by BvgAS. Causes disruption of tight junctions, damage 
to cilia with ciliary stasis, IL-1 and NO production. 
    LOS Envelope toxin. Often referred to as lipooligosaccharide (LOS) 
because it lacks O-antigen. Endotoxin activities. Role in antibiotic 
and serum resistance. Cause of whole cell vaccines reactogenicity. 
    Type III secretion system 
   (T3SS)    
Translocate effector proteins into host cells. Required for persistent 
tracheal colonization. Immunomodulatory activity. Activates 
ERK1/2.  
   Autotransporters 
   (BrkA, TcfA, Vag8, SphB1) 
Surface-associated or secreted. Putative roles in mediating 
adherence, serum resistance, evasion of antibody-mediated 
clearance, proteolytic processing of other surface proteins. 
Table 1. B. pertussis main virulence determinants. Adapted from (Mattoo and Cherry 2005)
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FIG. 1. B. pertussis pathogenesis: transmission and disease progression Adapted from (Tozzi, Celentano et al. 2005). Bordetella pertussis engages multiple strategies in order 
to create a niche for colonization of the mucosal epithelium. From left to the right: several virulence factors mediate adhesion to respiratory cells (FHA, 69K, Fimbriae), 
colonization and dissemination. Bordetella pertussis evades the immune system and the complement mediated killing (BrkA and Vag8) and invades epithelial cells. Tracheal 
cytotoxin (TCT) and lipo-oligosaccharide (LOS) synergistically evoke ciliary damage to the respiratory epithelium. Pertussis Toxin (PT), Adenylate cyclase toxin (ACT) and the 
type III secretion system (T3SS) subvert intraepithelial signaling pathways leading to cytotoxicity.  
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1.1.2. Pertussis vaccines and resurgence of pertussis 
In the pre-vaccine era, pertussis was an endemic and epidemic disease mainly affecting 
young children, with high morbidity and mortality (Cherry 1999). Given the severity of 
the disease, vaccines were introduced soon after the isolation of the etiological agent, to 
treat and prevent the disease. Whole-cell pertussis (wP) vaccines, that consist of 
suspensions of killed B. pertussis organisms (Xing, Markey et al. 2014), were first 
introduced in the 1940s and mass vaccination programs resulted in a rapid reduction in 
both the incidence of pertussis and the number of death caused by the infection in all 
age groups. However, the high reactogenicity of wP vaccines due to the presence of 
endotoxin, including an elevated risk of fever (Barkin and Pichichero 1979) and rare 
cases of convulsions, motivated the development in the 1980s of acellular pertussis (aP) 
vaccines. aP vaccines, consisting of one to five purified antigens (PT, FHA, PRN and 
FIM 2/3), are less reactogenic, thanks to the removal of the LPS, and starting from the 
late 1990s progressively replaced wP vaccines in many developed countries. Since then, 
in the last three decades a steady increase in the number of pertussis cases was observed 
in various countries following aP vaccination programs (Black, Cousens et al. 2010, 
Chiappini, Stival et al. 2013, Ausiello and Cassone 2014, Mills, Ross et al. 2014), 
confirming a reemergence of pertussis.  
There are several causes that may contribute to the resurgence of pertussis; one of these 
is the emergence of B. pertussis strains that have undergone variations in the antigens 
included in the vaccine, as consequence of immune selective pressure. Indeed, it has 
been reported in the past decade the appearance of B. pertussis strains with increased 
production of pertussis toxin and strains pertactin-deficient (de Gouw, Hermans et al. 
2014, Mooi, Van Der Maas et al. 2014). Antigenic divergence could affect both 
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memory recall and the efficacy of antibodies, while higher levels of pertussis toxin may 
increase suppression of the innate and acquired immune system.  
A second possible reason is the waning immunity. Although initially induced at a 
sufficiently protective level, the acquired pertussis-specific immunity is progressively 
lost with time. Estimates indicate that infection-acquired immunity against pertussis 
disease wanes after 4–20 years and protective immunity after vaccination with wP or aP 
vaccines wanes after 4–12 years. (Wendelboe, Van Rie et al. 2005, Klein, Bartlett et al. 
2012). There is also evidence that some wP vaccines induce longer lasting immunity 
than aP vaccines (Mooi, Van Der Maas et al. 2014). Further research into the rate of 
waning of vaccine-acquired immunity will help to determine the optimal timing and 
frequency of booster immunizations and their role in pertussis control. 
Another explanation for the increasing incidence of pertussis related to the switch to aP 
vaccines lies in the difference between the mechanisms of both humoral and cellular 
immunity induced by natural infection or vaccination with a wP vaccine versus the 
vaccination with aP vaccine. Studies in murine models have shown that innate immune 
response help to control bacterial infection, while the complete clearance of bacteria 
requires cellular immunity mediated by T cells that secrete IFN- γ (T-helper type 1, 
Th1) and IL-17 (T-helper type 17, Th17) (Higgs, Higgins et al. 2012, Ross, Sutton et al. 
2013). Complementary studies have shown that natural infection with B. pertussis or 
immunization with wP vaccines, which contain killed bacteria, promote naïve T-cell 
differentiation into Th1 and Th17 types, which promote bacterial killing by activation of 
macrophages and neutrophils and induction of IgG2a opsonizing antibodies. On the 
contrast, current aP vaccines, containing three to five purified antigens, promote naïve 
T-cell differentiation into Th17 cells, which activate neutrophils, and Th2 cells, which 
promote eosinophil activation, with no known protective role, and induction of toxin-
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neutralizing IgG1 antibodies (Higgs, Higgins et al. 2012). These findings were also 
confirmed by a recent study with a baboon model, in which animals showed the same 
type of immunity response (Warfel, Zimmerman et al. 2014). Importantly, baboons 
immunized with aP vaccines were protected from pertussis-associated symptoms but 
not from colonization and were able to transmit the disease to unimmunized animals. 
By contrast, immunization with wP vaccines resulted in a more rapid B. pertussis 
clearance.  
The observation that aP vaccines, which induce a different immune response from 
natural infection, fail to prevent colonization and transmission, in addition to waning 
immunity and the emergence of strains with mutated antigens, provides a plausible 
explanation of pertussis resurgence and suggests that control of the disease requires the 
development of improved vaccines (Clark, Messonnier et al. 2012).  
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1.2. Outer Membrane Vesicles 
Outer Membrane Vesicles (OMV) are blebs of the outer membrane that are 
spontaneously released by virtually any Gram-negative bacteria (Haurat, Elhenawy et 
al. 2015, Schwechheimer and Kuehn 2015). Although the observation of OMV release 
was made over 40 years ago, only in the past 10 years their study has become focused 
on their functions and biologica roles, especially as they relate to bacterial pathogenesis. 
This phenomenon happens in very different settings, including planktonic cultures, 
surface-attached biofilm communities, solid and liquid media, and natural environments 
such as fresh and salt water or mammalian hosts (Beveridge, Makin et al. 1997, 
Beveridge 1999, Hellman, Loiselle et al. 2000, Biller, Schubotz et al. 2014). OMV are 
spherical and bilyered structure and they range from 50 to 250 nm in size. Clearly, 
being liberated from the outer membrane, OMV contain lipopolysaccharide (LPS), 
outer membrane proteins and phospholipids, along with periplasmic proteins in their 
lumen (McBroom, Johnson et al. 2006). 
To better understand the mechanisms that are involved in OMV biogenesis it is 
important to consider the peculiar architecture of the bacterial cell envelope. Indeed, the 
budding and detachment of OMV depends on speficic interactions between the bacterial 
outer membrane and the underlying peptidoglycan layer (Braun and Wolff 1975, 
Cascales, Bernadac et al. 2002). In particular, specific crosslinks determine envelope 
stability, give bacteria their shape and confer protection from osmotic changes and sheer 
stress. OMV biogenesis therefore must rely on the dissociation of the outer membrane 
from the peptidoglycan layer in specific areas were attachments are depleted or missing. 
The budding vesicles then bulge outwards until the membrane undergoes fission and 
detaches (Schwechheimer and Kuehn 2015).  
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OMV are largely described in literature for their multifaceted roles in bacterial 
physiology and pathogenesis. The various functions attributed to OMV can be classified 
in two main groups: response to physical and chemical stress and delivery of 
biomolecules. Therefore, bacteria can utilize OMV either to improve their chances for 
survival or to induce changes in their environment, including both the host and the 
surrounding bacterial community.  
Within the first group of biological roles we can list resistance to antibiotics and 
antimicrobial peptides and protection from antibodies and bacteriophages (Manning and 
Kuehn 2011). Also, OMV can act to remove toxic compounds from bacterial cells, such 
as misfolded proteins during temperature stress (McBroom and Kuehn 2007).  
On the other hand, within the second group of described functions, we can list different 
types of OMV cargo, ranging from proteins to saccharides and nucleic acids. OMV are 
described to stimulate the immune system by presenting antigenic outer membrane 
components and LPS (Alaniz, Deatherage et al. 2007), to deliver autolysins to 
competing bacterial species, and to be involved in horizontal DNA transfer (Dorward, 
Garon et al. 1989). OMV can serve as sources of carbon and nitrogen (Biller, Schubotz 
et al. 2014), and can carry enzymes able to digest complex biomolecules during nutrient 
stress (Toledo, Coleman et al. 2012). They were also involved in iron and zinc 
acquisition, providing bacteria with access to essential metals (Dashper, Hendtlass et al. 
2000, Smalley, Byrne et al. 2011, Prados-Rosales, Weinrick et al. 2014). Finally, they 
were shown to assist in quorum sensing and biofilm formation (Mashburn-Warren, 
Howe et al. 2009). Most interestingly, when they are released from Gram-negative 
pathogens, OMV have been found to be enriched with active toxins and other virulence 
factors that enables them to interact with host cell and contribute to intoxication 
(Fiocca, Necchi et al. 1999, Kesty, Mason et al. 2004, Chatterjee and Chaudhuri 2011).  
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2. Chapter one: OMV-based and proteomic driven 
antigen selection for a new generation vaccine against 
pertussis 
Despite high vaccination coverage world-wide, whooping cough is recently increasing 
in occurrence suggesting that novel vaccine formulations targeted at the prevention of 
colonization and transmission should be investigated. In order to identify new 
candidates for inclusion in the acellular formulation, we used spontaneously released 
outer membrane vesicles (OMV) as a potential source of key adhesins. The ability of 
anti-OMV serum to inhibit the adhesion of B. pertussis to lung epithelial cells in vitro 
was demonstrated. We employed a proteomic approach to quantify proteins in OMV 
purified from bacteria in the Bvg+ and Bvg- phase, thus comparing the outer membrane 
protein pattern of this pathogen in its virulent or avirulent state. Six of the most 
abundant outer membrane proteins were selected as candidates to be evaluated for their 
adhesive properties and vaccine potential. We generated E. coli strains singularly 
expressing the selected proteins and assessed their ability to adhere to lung epithelial 
cells in vitro. Four out of the selected proteins conferred adhesive ability to E. coli. 
Three of the candidates were specifically detected by anti-OMV mouse serum 
suggesting that these proteins are immunogenic antigens able to elicit an antibody 
response when displayed on the OMV. Anti-OMV serum was able to inhibit only BrkA-
expressing E. coli adhesion to lung epithelial cells. Finally, stand-alone immunization of 
mice with recombinant BrkA resulted in significant protection against infection of the 
lower respiratory tract after challenge with B. pertussis. Taken together, these data 
support the inclusion of BrkA and possibly further adhesins to the current acellular 
pertussis vaccines to improve the impact of vaccination on the bacterial clearance. 
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2.1. Results 
OMV purification, visualization, enumeration and sizing 
In order to identify possible Bvg-regulated outer membrane adhesins, we compared the 
protein composition of OMV from two B. pertussis strains, the Tohama I-derivatives 
BP536 and BP537 representative of the Bvg+ and Bvg- phases, respectively.  
OMV were purified using a detergent-free method from cell-free culture supernatants 
through ultracentrifugation. Equal amounts with respect to total protein quantities from 
both preparations were loaded onto SDS-PAGE gel (Fig. 2A) showing significant 
differences between the two samples representing Bvg+ and Bvg- phases. Several high 
molecular weight protein bands appear to be exclusive to Bvg+ OMV, as well as two 
major bands with apparent molecular weight of 42 and 32 kDa, while one intense 
protein band of apparent molecular weight around 40 kDa seems to be majorly 
expressed in Bvg- OMV. The 40 kDa protein band was excised, destained and digested 
with trypsin for peptide mass fingerprinting (PMF) identification: outer membrane porin 
protein BP0840 was identified with a sequence coverage of 42% (data not shown).  
To evaluate the actual number and the size of vesicles we used nanoparticle tracking 
analysis (NTA), a method for direct, real-time visualization of nanoparticles in liquids 
through the tracking of the brownian movement of individual particles (Olaya-Abril, 
Prados-Rosales et al. 2014). OMV samples from BP536 and BP537, normalized to the 
same protein concentration of 1 mg/mL, contained 6 x10
11
/mL and 6.3 x 10
11
/mL 
OMV-particles, respectively. The size distribution of OMV isolated from both strains 
was in the 70–230 nm diameter range with the majority of the OMV particles at 115 nm 
(Fig. 2B). These results indicated that, despite the dramatic difference in protein 
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composition of the two OMV samples, 1 mg of proteins from each OMV preparation as 
measured with the Lowry assay, corresponds to the same number of vesicles (around 6 
x 10
11
 blebs). 
 
FIG. 2. SDS-PAGE and nanoparticle tracking analysis of OMV samples from BP536 and BP537. 
(A) SDS-PAGE and Coomassie blue staining of 10 µg (protein content) of OMV samples from B. 
pertussis BP536 Bvg+ (lane 1) and its Bvg- derivative BP537 (lane 2). (B) Nanoparticle tracking analysis 
measurement of OMV preparation (1 mg protein/mL) showing the sizes and total number of OMV per 
mL. 
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Inhibition of B. pertussis adhesion with anti-OMV serum 
We checked whether antibodies raised against antigens present in Bvg+ OMV could 
have anti-adhesive properties on B. pertussis. We tested the ability of anti-OMV sera to 
inhibit adhesion of BP536 to A549 respiratory epithelial cells. Fluorescent bacteria were 
pre-incubated with mouse pooled sera in a range of four dilutions and A549 cells were 
infected as described previously (Zanaboni, Arato et al. 2016). Mouse anti-sera were 
raised to Bvg+ OMV and whole bacteria adsorbed to aluminum hydroxide and collected 
after the third immunization together with control sera from mice immunized with 
adjuvant only. We found that anti-OMV serum conferred a substantial reduction of 
adhering bacteria even at low serum concentrations. Interestingly, sera raised against 
whole bacteria, therefore targeting the entire membrane antigen repertoire, showed a 
comparable kinetic of inhibition. Anti-alum serum was included in the experiments as 
negative control and, as expected, did not induce any inhibition of B. pertussis adhesion 
(Fig. 3).  
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FIG. 3. Impact of anti-OMV serum on B. pertussis adhesion to A549 cells. Sera from 10 mice 
immunized with either OMV, whole bacteria or aluminum hydroxide as control were pooled, serially 
diluted in infection medium and incubated with labeled wild-type B. pertussis BP536 for 1 h. A549 cells 
were then infected with the bacteria/sera mixtures for 1 hour and, after extensive washes to remove 
unbound bacteria, cell-associated bacteria were quantified by fluorescence reading at Ex/Em 485/535 nm. 
Results represent mean ± SD of one representative of three independent experiments each performed in 
triplicates. 
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Comparative proteomic analysis 
OMV samples from BP536 and BP537 were digested by trypsin after TCA 
precipitation. Proteomic analysis was performed by LC-MS/MS using a Data-
Dependent Acquisition (DDA) approach. A total of 155 and 247 proteins were 
quantified in the first and second biological replicate respectively, with the second 
replicate fully including the proteins quantified in the first one. Percentages of each 
protein in the total samples were averaged to calculate the fold increase of each protein 
amount in one Bvg phase with the respect to the other (Table 2). Despite some proteins 
were identified exclusively in either Bvg+ or Bvg- phase, we set a threshold to 
determine the Bvg phase specificity: 23 proteins showed a 10-fold increase in Bvg+ vs. 
Bvg- phase and represented ~58% of the total protein amount in Bvg+ OMV while 26 
proteins showed a 10-fold increase in Bvg- vs. Bvg+ phase and represented ~14% of the 
total protein amount in Bvg- OMV (Fig. 4A). The localization of the quantified proteins 
was predicted according to PSORTb software and refined for lipoprotein annotation 
using DOLOP software. The analysis predicted ~90% and ~75% of outer membrane 
proteins, lipoproteins, extracellular and periplasmic proteins for Bvg+ and Bvg- OMV, 
respectively (Fig. 4B). Around 10% of the identified proteins had an unknown 
prediction of localization in both OMV samples but only a minority of proteins was 
predicted to be inner membrane or cytoplasmic, thus confirming that vesicles are 
generated by outer membrane blebbing and not by bacterial lysis. This analysis 
confirmed the main differences already observed in the SDS-PAGE gel, identifying the 
five most abundant proteins in Bvg+ OMV to have a theoretical molecular weight 
higher than 90 kDa and the most abundant protein in Bvg- OMV to be the outer 
membrane porin protein BP0840 (~20%).  
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FIG. 4. Comparative proteomic analysis of B. pertussis OMV: protein quantification through LC-
MS/MS and prediction of their subcellular localization. (A) Protein quantification of Bvg+ and Bvg- 
OMV: proteins with 10-fold amount increase in Bvg+ vs. Bvg- OMV (light blue), proteins with 10-fold 
amount increase in Bvg- vs. Bvg+ OMV (dark blue), unregulated proteins (grey). (B) Distribution of 
quantified proteins in the distinct subcellular localizations based on prediction with PSORTb and DOLOP 
softwares: Outer Membrane (OM), Periplasm (P), Lipoproteins (L) Inner Membrane (IM), Cytoplasm 
(C), Extracellular (Ex), Unknown (U).  
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Accession Description [Bordetella pertussis Tohama I] % BVG+ % 
BVG- 
Fold increase 
Bvg+ vs. Bvg- 
Fold increase 
Bvg- vs. Bvg+ 
PSORTb DOLOP  
NP_880571.1 filamentous hemagglutinin/adhesin 16,64% 0,01% 1760,96 0,00 Outer Membrane  
NP_882013.1 BrkA autotransporter   11,82% 0,04% 313,79 0,00 Outer Membrane  
NP_879839.1 pertactin autotransporter   8,46% 0,00% 1771,79 0,00 Outer Membrane  
NP_879104.1 autotransporter subtilisin-like protease SphB1   6,50% 0,00% 3284,82 0,00 Outer Membrane  
NP_880953.1 Vag8 autotransporter   4,72% 0,00% 1421,45 0,00 Outer Membrane  
NP_881876.1 translocation protein TolB   3,86% 8,69% 0,44 2,25 Periplasmic  
NP_879974.1 tracheal colonization factor   3,77% 0,00% 3094,18 0,00 Outer Membrane  
NP_879893.1 outer membrane ligand binding protein   3,42% 0,74% 4,60 0,22 Outer Membrane  
NP_879898.1 serotype 2 fimbrial subunit   3,03% 0,00% 5846,89 0,00 Extracellular  
NP_882014.1 molecular chaperone GroEL   2,82% 3,73% 0,75 1,32 Cytoplasmic  
NP_879650.1 outer membrane porin protein BP0840   2,75% 20,28% 0,14 7,38 Outer Membrane  
NP_879093.1 exported protein   2,24% 2,15% 1,04 0,96 Unknown lipo 
NP_882074.1 peptidyl-prolyl cis-trans isomerase   2,19% 2,18% 1,01 0,99 Periplasmic  
NP_882329.1 amino acid ABC transporter substrate-binding protein   1,50% 1,25% 1,20 0,83 Periplasmic  
NP_879666.1 TonB-dependent receptor BfrD   1,48% 0,01% 171,18 0,01 Outer Membrane  
NP_881875.1 peptidoglycan-associated lipoprotein   1,28% 2,76% 0,46 2,15 Outer Membrane lipo 
NP_880337.1 iron binding protein   1,18% 0,37% 3,24 0,31 Periplasmic  
NP_880224.1 ABC transporter substrate-binding protein   1,17% 0,75% 1,56 0,64 Unknown  
NP_881568.1 lipoprotein   1,13% 1,71% 0,66 1,52 Outer Membrane lipo 
NP_879744.1 outer membrane protein A   1,06% 1,26% 0,84 1,19 Outer Membrane  
NP_881062.1 serine protease   0,90% 2,95% 0,31 3,27 Periplasmic  
NP_880436.1 peptidase   0,69% 1,59% 0,43 2,32 Outer Membrane  
NP_881028.1 peptide ABC transporter substrate-binding protein   0,68% 0,01% 58,54 0,02 Periplasmic  
NP_880575.1 filamentous hemagglutinin transporter protein FhaC   0,66% 0,07% 9,06 0,11 Outer Membrane  
NP_879258.1 exported protein   0,61% 1,28% 0,48 2,09 Periplasmic lipo 
NP_880303.1 lipoprotein   0,60% 4,37% 0,14 7,27 Unknown lipo 
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NP_879135.1 exported protein   0,56% 0,68% 0,82 1,23 Periplasmic  
NP_880049.1 sn-glycerol-3-phosphate ABC transporter substrate-binding protein UgpB   0,56% 1,82% 0,31 3,27 Periplasmic  
NP_881874.1 hypothetical protein BP3341   0,54% 1,43% 0,38 2,64 Unknown  
NP_879068.1 lipoprotein   0,45% 0,09% 4,83 0,21 Unknown lipo 
NP_881542.1 ABC transporter substrate-binding protein   0,42% 0,33% 1,30 0,77 Unknown  
NP_880721.1 glycine/betaine ABC transporter substrate-binding protein   0,40% 0,61% 0,65 1,53 Periplasmic  
NP_880844.1 outer membrane protein assembly factor BamB   0,37% 0,90% 0,41 2,43 Outer Membrane  
NP_881124.1 zinc protease   0,37% 0,39% 0,94 1,06 Outer Membrane  
NP_879378.1 autotransporter  BP0529   0,36% 0,02% 14,91 0,07 Outer Membrane  
NP_881639.1 adenosylhomocysteinase   0,36% 0,18% 2,02 0,49 Cytoplasmic  
NP_881351.1 ABC transporter substrate-binding protein   0,33% 1,64% 0,20 4,97 Periplasmic  
NP_881504.1 TonB-dependent receptor   0,30% 2,76% 0,11 9,33 Outer Membrane  
NP_881019.1 enolase   0,28% 0,39% 0,71 1,40 Cytoplasmic  
NP_880170.1 outer membrane protein   0,27% 0,97% 0,27 3,64 Periplasmic  
NP_881493.1 DNA-binding protein   0,26% 0,03% 9,57 0,10 Unknown  
NP_882283.1 pertussis toxin subunit 2   0,26% 0,00% #DIV/0! 0,00 Unknown  
NP_879610.1 polyribonucleotide nucleotidyltransferase   0,22% 0,31% 0,72 1,39 Cytoplasmic  
NP_879922.1 outer membrane protein assembly factor   0,22% 0,59% 0,37 2,69 Outer Membrane lipo 
NP_880169.1 outer membrane protein assembly factor   0,22% 0,79% 0,27 3,67 Outer Membrane  
NP_880053.1 leu/Ile/val-binding protein   0,21% 0,46% 0,47 2,13 Periplasmic  
NP_880738.1 efflux system inner membrane protein   0,21% 1,79% 0,12 8,38 Cytoplasmic 
Membrane 
 
NP_881866.1 chaperone SurA   0,21% 0,56% 0,38 2,66 Periplasmic  
NP_880063.1 lipoprotein   0,20% 0,61% 0,32 3,10 Unknown lipo 
NP_882317.1 hypothetical protein BP3819   0,19% 0,52% 0,38 2,66 Unknown  
NP_879005.1 penicillin-binding protein   0,19% 1,93% 0,10 10,40 Cytoplasmic 
Membrane 
 
NP_879899.1 NADP-dependent malic enzyme   0,18% 0,03% 6,15 0,16 Cytoplasmic  
NP_879406.1 amino acid ABC transporter substrate-binding protein   0,17% 0,83% 0,21 4,80 Periplasmic  
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NP_878925.1 elongation factor Tu   0,17% 0,85% 0,20 4,95 Cytoplasmic  
NP_882263.1 lipoprotein   0,15% 0,09% 1,74 0,58 Outer Membrane lipo 
NP_882282.1 pertussis toxin subunit 1   0,15% 0,00% #DIV/0! 0,00 Extracellular  
NP_879312.1 exported protein   0,15% 7,15% 0,02 47,22 Unknown  
NP_879963.1 lipoprotein   0,15% 0,07% 1,98 0,50 Outer Membrane lipo 
NP_879023.1 glycerol-3-phosphate ABC transporter substrate-binding protein   0,15% 0,00% 145,71 0,01 Periplasmic  
NP_882284.1 pertussis toxin subunit 4   0,14% 0,00% #DIV/0! 0,00 Unknown  
NP_879606.1 ketol-acid reductoisomerase   0,13% 0,10% 1,33 0,75 Cytoplasmic  
NP_882045.1 DNA-binding protein HU-beta   0,13% 0,07% 1,72 0,58 Unknown  
NP_881135.1 Outer membrane protein assembly factor BamE   0,13% 0,41% 0,31 3,24 Unknown  
NP_880780.1 exported protein   0,12% 0,62% 0,20 4,99 Extracellular lipo 
NP_879256.1 exported protein   0,12% 0,73% 0,17 6,03 Cytoplasmic 
Membrane 
 
NP_879501.1 exported protein   0,12% 0,38% 0,32 3,11 Periplasmic  
NP_882347.1 catalase   0,12% 0,08% 1,45 0,69 Periplasmic  
NP_879904.1 2-oxoglutarate dehydrogenase complex subunit dihydrolipoamide 
succinyltransferase   
0,12% 0,05% 2,31 0,43 Cytoplasmic  
NP_882286.1 pertussis toxin subunit 3   0,11% 0,00% #DIV/0! 0,00 Unknown  
NP_881063.1 sigma factor regulatory protein   0,10% 0,16% 0,62 1,61 Periplasmic  
NP_879065.1 bacterioferritin   0,10% 0,23% 0,42 2,36 Cytoplasmic  
NP_880264.1 extracellular solute-binding protein   0,10% 0,05% 1,90 0,53 Periplasmic  
NP_880329.1 glutamine synthetase   0,10% 0,03% 3,75 0,27 Cytoplasmic  
NP_881814.1 thiol:disulfide interchange protein   0,09% 0,28% 0,33 3,06 Periplasmic  
NP_879452.1 carboxy-terminal processing protease   0,09% 0,27% 0,33 3,05 Cytoplasmic 
Membrane 
 
NP_880306.1 glutamine ABC transporter substrate-binding protein   0,08% 0,12% 0,71 1,41 Periplasmic  
NP_881933.1 outer membrane porin protein OmpQ   0,08% 0,00% #DIV/0! 0,00 Outer Membrane  
NP_881966.1 exported protein   0,08% 0,09% 0,85 1,18 Unknown  
NP_881275.1 ABC transporter substrate-binding protein   0,08% 0,01% 6,87 0,15 Periplasmic  
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NP_881784.1 peptide ABC transporter substrate-binding protein   0,08% 0,11% 0,72 1,38 Periplasmic  
NP_880714.2 DNA-binding protein Bph2   0,08% 0,04% 2,14 0,47 Cytoplasmic  
NP_881280.1 adhesin FhaS   0,08% 0,01% 6,30 0,16 Outer Membrane  
NP_880732.1 exported protein   0,07% 0,07% 1,08 0,93 Unknown  
NP_880573.1 outer membrane usher protein FimC   0,07% 0,00% #DIV/0! 0,00 Outer Membrane  
NP_880572.1 chaperone protein FimB/FhaD   0,07% 0,00% 139,94 0,01 Periplasmic  
NP_879836.1 D-alanyl-D-alanine carboxypeptidase   0,07% 0,91% 0,08 12,67 Periplasmic  
NP_882081.1 exported protein   0,07% 0,02% 3,94 0,25 Periplasmic  
NP_880577.1 exported protein   0,07% 0,08% 0,86 1,17 Periplasmic  
NP_881416.1 lipoprotein   0,07% 0,44% 0,15 6,78 Cytoplasmic 
Membrane 
 
NP_882264.1 exported protein   0,06% 0,06% 1,01 0,99 Unknown  
NP_879015.1 thiol:disulfide interchange protein DsbA   0,06% 0,04% 1,77 0,57 Periplasmic  
NP_881828.1 ATP synthase subunit alpha   0,06% 0,01% 4,66 0,21 Cytoplasmic  
NP_881191.1 lipoprotein   0,06% 0,30% 0,20 4,89 Unknown lipo 
NP_881050.1 cytosol aminopeptidase   0,06% 0,04% 1,44 0,70 Cytoplasmic  
NP_881830.1 ATP synthase subunit beta   0,06% 0,01% 6,62 0,15 Cytoplasmic  
NP_879712.1 peptidase   0,06% 0,04% 1,32 0,76 Unknown  
NP_880524.1 glycerol-3-phosphate ABC transporter substrate-binding protein   0,06% 0,05% 1,03 0,97 Periplasmic  
NP_879609.1 30S ribosomal protein S15   0,05% 0,07% 0,80 1,25 Cytoplasmic  
NP_879842.1 membrane protein   0,05% 0,02% 2,78 0,36 Unknown  
NP_880735.1 lipoprotein   0,05% 0,15% 0,36 2,75 Unknown lipo 
NP_880592.1 peptidyl-prolyl cis-trans isomerase B   0,05% 0,12% 0,42 2,39 Cytoplasmic  
NP_882088.1 exported protein   0,05% 0,01% 9,19 0,11 Unknown  
NP_880868.1 autotransporter   0,05% 0,11% 0,46 2,20 Outer Membrane  
NP_881247.1 inosine-5'-monophosphate dehydrogenase   0,05% 0,05% 1,01 0,99 Cytoplasmic  
NP_880725.1 beta-ketothiolase   0,05% 0,07% 0,65 1,54 Cytoplasmic  
NP_881631.1 transglycosylase   0,04% 0,19% 0,23 4,34 Periplasmic  
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NP_880879.1 type III secretion protein   0,04% 0,00% 9,48 0,11 Outer Membrane  
NP_879855.1 phosphate ABC transporter substrate-binding protein PstS   0,04% 0,16% 0,27 3,68 Periplasmic  
NP_880574.1 fimbrial adhesin   0,04% 0,00% #DIV/0! 0,00 Extracellular  
NP_880108.1 exported protein   0,04% 0,02% 2,51 0,40 Unknown  
NP_881812.1 membrane-bound transglycosylase   0,04% 0,19% 0,20 5,02 Unknown lipo 
NP_881126.1 chaperone protein DnaK   0,04% 0,07% 0,52 1,91 Cytoplasmic  
NP_879408.1 exported protein   0,04% 0,05% 0,78 1,29 Periplasmic  
NP_882325.1 exported protein   0,04% 0,06% 0,66 1,52 Unknown  
NP_882066.1 peroxiredoxin   0,04% 0,03% 1,25 0,80 Cytoplasmic  
NP_882235.1 exported protein   0,04% 0,07% 0,49 2,03 Outer Membrane  
NP_879409.1 exported protein   0,04% 0,08% 0,44 2,28 Unknown  
NP_880114.1 amino acid ABC transporter substrate-binding protein   0,03% 1,48% 0,02 44,97 Periplasmic  
NP_879067.1 lipoprotein   0,03% 0,06% 0,51 1,97 Unknown lipo 
NP_880267.1 amino acid-binding periplasmic protein   0,03% 0,01% 3,20 0,31 Periplasmic  
NP_879314.1 heme receptor HemC   0,03% 0,00% 8,17 0,12 Outer Membrane  
NP_879807.1 exported protein   0,03% 0,16% 0,18 5,43 Unknown lipo 
NP_881587.1 membrane protein   0,03% 0,03% 0,97 1,03 Unknown  
NP_881196.1 lipoprotein   0,03% 0,13% 0,21 4,73 Unknown lipo 
NP_879636.1 azurin   0,03% 0,08% 0,34 2,95 Periplasmic  
NP_880994.1 citrate synthase   0,03% 0,07% 0,39 2,58 Cytoplasmic  
NP_880045.1 leucine/isoleucine/valine ABC transporter substrate-binding protein   0,03% 0,02% 1,17 0,86 Periplasmic  
NP_882085.1 glycine/betaine ABC transporter substrate-binding protein   0,03% 0,06% 0,47 2,14 Periplasmic  
NP_881539.1 N-acetyl-gamma-glutamyl-phosphate reductase   0,03% 0,01% 2,18 0,46 Cytoplasmic  
NP_880241.1 amino acid ABC transporter substrate-binding protein   0,03% 0,07% 0,37 2,72 Unknown  
NP_881692.1 outer membrane lipoprotein LolB   0,02% 0,09% 0,29 3,48 Unknown lipo 
NP_882015.1 co-chaperonin GroES   0,02% 0,12% 0,19 5,19 Cytoplasmic  
NP_881501.1 lipoprotein   0,02% 0,08% 0,28 3,63 Outer Membrane lipo 
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NP_879524.1 lipoprotein   0,02% 0,06% 0,35 2,85 Unknown lipo 
NP_879539.1 aspartate--tRNA ligase   0,02% 0,02% 1,30 0,77 Cytoplasmic  
NP_881365.1 superoxide dismutase   0,02% 0,03% 0,78 1,28 Periplasmic  
NP_882357.1 peptide ABC transporter substrate-binding protein   0,02% 0,01% 4,17 0,24 Periplasmic  
NP_881413.1 hypothetical protein BP2815   0,02% 0,01% 2,46 0,41 Unknown  
NP_881382.1 lipoprotein   0,02% 0,02% 1,32 0,76 Unknown lipo 
NP_879179.1 ABC transporter substrate-binding protein   0,02% 0,04% 0,52 1,92 Periplasmic  
NP_880217.1 exported protein   0,02% 0,11% 0,19 5,40 Unknown  
NP_882152.1 50S ribosomal protein L17   0,02% 0,04% 0,48 2,08 Cytoplasmic  
NP_879154.1 stringent starvation protein A   0,02% 0,01% 1,38 0,72 Cytoplasmic  
NP_881865.1 LPS-assembly protein LptD   0,02% 0,04% 0,51 1,98 Outer Membrane  
NP_880864.1 cell surface protein   0,02% 0,03% 0,62 1,62 Unknown  
NP_879131.1 N-acetylmuramoyl-L-alanine amidase   0,02% 0,02% 0,81 1,23 Cytoplasmic  
NP_880586.1 exported protein   0,02% 0,02% 0,72 1,39 Unknown  
NP_881648.1 outer membrane protein   0,02% 0,16% 0,11 9,23 Outer Membrane  
NP_879309.1 acetylornithine transaminase   0,02% 0,04% 0,40 2,50 Cytoplasmic  
NP_879334.1 sulfite oxidase subunit YedY   0,02% 0,00% 18,90 0,05 Unknown  
NP_880221.1 aspartate-semialdehyde dehydrogenase   0,02% 0,07% 0,22 4,50 Cytoplasmic  
NP_881167.1 succinyl-CoA ligase subunit alpha   0,02% 0,49% 0,03 31,90 Cytoplasmic  
NP_880986.1 putrescine ABC transporter substrate-binding protein   0,02% 0,02% 0,62 1,61 Periplasmic  
NP_881001.1 malate dehydrogenase   0,02% 0,04% 0,39 2,56 Cytoplasmic  
NP_882247.1 cytochrome c oxidase subunit 2   0,02% 0,04% 0,38 2,65 Cytoplasmic 
Membrane 
 
NP_880476.1 2 3 4 5-tetrahydropyridine-2 6-carboxylate N-succinyltransferase   0,01% 0,01% 1,27 0,79 Cytoplasmic  
NP_881473.1 c'cytochrome   0,01% 0,03% 0,55 1,81 Periplasmic  
NP_880458.1 peptidoglycan-binding protein   0,01% 0,02% 0,62 1,62 Cytoplasmic 
Membrane 
 
NP_879905.1 2-oxoglutarate dehydrogenase complex subunit dihydrolipoamide 
dehydrogenase   
0,01% 0,01% 2,66 0,38 Cytoplasmic  
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NP_880776.1 glutathione reductase   0,01% 0,02% 0,65 1,54 Cytoplasmic  
NP_881115.1 isocitrate dehydrogenase   0,01% 0,09% 0,14 6,94 Cytoplasmic  
NP_882134.1 aldehyde dehydrogenase   0,01% 0,01% 1,66 0,60 Cytoplasmic  
NP_879841.1 membrane protein   0,01% 0,02% 0,58 1,74 Unknown  
NP_881695.1 cyclase   0,01% 0,04% 0,27 3,74 Cytoplasmic  
NP_881693.1 hypothetical protein BP3128   0,01% 0,02% 0,69 1,46 Unknown  
NP_881168.1 succinyl-CoA ligase subunit beta   0,01% 0,13% 0,09 11,44 Cytoplasmic  
NP_881781.1 osmotically inducible lipoprotein B   0,01% 0,03% 0,39 2,60 Unknown lipo 
NP_882271.1 imidazoleglycerol-phosphate dehydratase   0,01% 0,01% 1,29 0,78 Cytoplasmic  
NP_881374.1 short-chain dehydrogenase   0,01% 0,04% 0,30 3,32 Cytoplasmic  
NP_880304.1 4-hydroxy-tetrahydrodipicolinate synthase   0,01% 0,01% 1,07 0,94 Cytoplasmic  
NP_880836.1 adenylosuccinate synthetase   0,01% 0,02% 0,60 1,68 Cytoplasmic  
NP_882170.1 single-strand DNA-binding protein   0,01% 0,02% 0,68 1,48 Cytoplasmic  
NP_881665.1 molybdate ABC transporter substrate-binding protein ModA   0,01% 0,30% 0,03 31,87 Periplasmic  
NP_879417.1 exported protein   0,01% 0,09% 0,10 9,98 Unknown  
NP_879686.1 lipoprotein   0,01% 0,02% 0,45 2,25 Unknown lipo 
NP_880302.1 serotype 3 fimbrial subunit   0,01% 0,00% 8,55 0,12 Extracellular  
NP_879680.1 exported protein   0,01% 0,02% 0,53 1,89 Unknown  
NP_880801.1 exported protein   0,01% 0,00% 15,11 0,07 Unknown  
NP_882120.1 elongation factor G   0,01% 0,07% 0,12 8,10 Cytoplasmic  
NP_880162.1 elongation factor Ts   0,01% 0,03% 0,28 3,60 Cytoplasmic  
NP_882233.1 bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-
phosphate N-acetyltransferase   
0,01% 0,01% 0,81 1,23 Cytoplasmic  
NP_879756.1 ADP-L-glycero-D-manno-heptose-6-epimerase   0,01% 0,01% 0,88 1,13 Cytoplasmic  
NP_879343.1 DNA polymerase III subunit beta   0,01% 0,01% 0,73 1,36 Cytoplasmic  
NP_880296.1 exported protein BP1561    0,01% 0,00% 6,29 0,16 Outer Membrane  
NP_878933.1 DNA-directed RNA polymerase subunit beta'   0,01% 0,03% 0,27 3,65 Cytoplasmic  
NP_881287.1 fimbrial protein   0,01% 0,00% 63,65 0,02 Extracellular  
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NP_881651.1 ABC transporter substrate-binding protein   0,01% 0,02% 0,42 2,37 Cytoplasmic 
Membrane 
 
NP_879451.1 peptidase   0,01% 0,06% 0,12 8,40 Unknown  
NP_879765.1 antioxidant protein   0,01% 0,55% 0,01 78,08 Cytoplasmic  
NP_881266.1 exported protein   0,01% 0,02% 0,44 2,29 Unknown  
NP_879209.1 exported protein   0,01% 0,01% 0,64 1,56 Periplasmic  
NP_880834.1 30S ribosomal protein S21   0,01% 0,01% 0,61 1,63 Cytoplasmic  
NP_880684.1 aconitate hydratase   0,01% 0,11% 0,06 16,49 Cytoplasmic  
NP_881490.1 phospho-2-dehydro-3-deoxyheptonate aldolase   0,01% 0,03% 0,21 4,69 Cytoplasmic  
NP_878936.1 peptidoglycan-binding protein   0,01% 0,02% 0,40 2,53 Unknown  
NP_881498.1 nucleotide-binding protein   0,01% 0,01% 0,78 1,28 Cytoplasmic  
NP_879794.1 glyceraldehyde-3-phosphate dehydrogenase   0,01% 0,99% 0,01 163,89 Cytoplasmic  
NP_879530.1 exported protein   0,01% 0,01% 0,52 1,92 Unknown  
NP_880485.1 trigger factor   0,01% 0,01% 0,55 1,83 Cytoplasmic  
NP_880438.1 exported protein   0,01% 0,07% 0,08 11,99 Periplasmic  
NP_882258.1 outer membrane protein   0,01% 0,01% 0,76 1,31 Outer Membrane  
NP_880997.1 succinate dehydrogenase flavoprotein subunit   0,01% 0,02% 0,25 3,94 Cytoplasmic 
Membrane 
 
NP_881474.1 adenylosuccinate lyase   0,01% 0,00% 1,88 0,53 Cytoplasmic  
NP_879519.1 exported protein   0,01% 0,01% 0,62 1,61 Periplasmic  
NP_880710.1 LPS-assembly lipoprotein LptE   0,00% 0,02% 0,22 4,61 Unknown lipo 
NP_879616.1 triosephosphate isomerase   0,00% 0,00% 0,97 1,03 Cytoplasmic  
NP_882148.1 30S ribosomal protein S13   0,00% 0,01% 0,68 1,47 Cytoplasmic  
NP_882131.1 50S ribosomal protein L29   0,00% 0,00% 1,54 0,65 Cytoplasmic  
NP_881531.1 serine hydroxymethyltransferase   0,00% 0,04% 0,10 9,79 Cytoplasmic  
NP_882109.1 thiazole synthase   0,00% 0,00% 0,96 1,04 Cytoplasmic  
NP_880202.1 lipoprotein   0,00% 0,01% 0,23 4,33 Unknown lipo 
NP_882053.1 ornithine carbamoyltransferase   0,00% 0,01% 0,32 3,11 Cytoplasmic  
NP_881859.1 binding-protein-dependent transport protein   0,00% 0,02% 0,21 4,74 Periplasmic  
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NP_881497.1 exported protein   0,00% 0,01% 0,30 3,36 Periplasmic  
NP_880599.1 aspartate kinase   0,00% 0,03% 0,12 8,20 Cytoplasmic  
NP_881402.1 exported protein   0,00% 0,02% 0,20 4,98 Unknown  
NP_881354.1 lipoprotein   0,00% 0,05% 0,06 15,65 Unknown lipo 
NP_882097.1 hypothetical protein BP3584   0,00% 0,01% 0,34 2,96 Cytoplasmic  
NP_880178.1 phosphoenolpyruvate synthase   0,00% 0,02% 0,15 6,82 Cytoplasmic  
NP_882020.1 exported protein   0,00% 0,02% 0,16 6,34 Periplasmic  
NP_879943.1 muramoyltetrapeptide carboxypeptidase   0,00% 0,01% 0,18 5,48 Unknown  
NP_881202.1 50S ribosomal protein L20   0,00% 0,00% 0,54 1,84 Cytoplasmic  
NP_881446.1 aromatic amino acid aminotransferase   0,00% 0,02% 0,15 6,81 Cytoplasmic  
NP_879766.1 sulfate-binding protein   0,00% 0,06% 0,04 25,87 Periplasmic  
NP_879832.1 secreted protein   0,00% 0,00% 0,86 1,17 Cytoplasmic 
Membrane 
 
NP_880073.1 bacterioferritin comigratory protein   0,00% 0,00% 0,51 1,96 Unknown  
NP_879384.1 carboxymuconolactone decarboxylase   0,00% 0,00% 137,64 0,01 Unknown  
NP_880450.1 exported protein   0,00% 0,01% 0,18 5,51 Periplasmic  
NP_881385.1 aminotransferase   0,00% 0,01% 0,20 5,12 Cytoplasmic  
NP_881159.1 hypothetical protein BP2532   0,00% 0,01% 0,20 5,07 Cytoplasmic  
NP_880356.1 capsular polysaccharide export protein   0,00% 0,04% 0,04 24,39 Outer Membrane lipo 
NP_880501.1 aromatic amino acid aminotransferase   0,00% 0,02% 0,11 9,33 Cytoplasmic  
NP_880234.1 translation initiation factor IF-3   0,00% 0,01% 0,19 5,14 Cytoplasmic  
NP_879751.2 30S ribosomal protein S1   0,00% 0,02% 0,09 11,40 Cytoplasmic  
NP_879762.1 electron transfer flavoprotein subunit beta   0,00% 0,02% 0,07 13,64 Cytoplasmic  
NP_879972.1 chaperone protein ClpB   0,00% 0,02% 0,07 14,45 Cytoplasmic  
NP_882128.1 50S ribosomal protein L22   0,00% 0,00% 0,30 3,29 Cytoplasmic  
NP_881779.1 cell division topological specificity factor   0,00% 0,00% 0,20 5,07 Cytoplasmic  
NP_879190.1 glutamate-1-semialdehyde 2 1-aminomutase   0,00% 0,01% 0,05 19,12 Cytoplasmic  
NP_879798.1 phosphate acetyltransferase   0,00% 0,01% 0,05 20,77 Unknown  
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NP_882151.1 DNA-directed RNA polymerase subunit alpha   0,00% 0,01% 0,05 20,29 Cytoplasmic  
NP_881778.1 septum site-determining protein   0,00% 0,01% 0,02 41,37 Cytoplasmic  
NP_882254.1 alcohol dehydrogenase   0,00% 0,01% 0,00 204,68 Cytoplasmic  
NP_881994.1 phosphopantetheine adenylyltransferase   0,00% 0,01% 0,00 417,36 Cytoplasmic  
NP_880652.1 succinate-semialdehyde dehydrogenase   0,00% 0,02% 0,00 #DIV/0! Cytoplasmic  
NP_879763.1 electron transfer flavoprotein subunit alpha   0,00% 0,06% 0,00 #DIV/0! Unknown  
NP_881967.1 hypothetical protein BP3441   0,00% 0,01% 0,00 #DIV/0! Unknown  
Table 2. Comparative proteomics data: proteins quantified in OMV from BP536 and BP537. With LC-MS-MS analysis, 247 proteins were identified and quantified in two 
biological replicates of Bvg+ (BP536) and Bvg- (BP537) OMV. For each protein, accession number and protein description of B. pertussis Tohama I database are listed. In 
addition, the average (n=2 biological replicates, n=3 technical replicates) of the calculated percentage for each protein in the total sample is given (Average 
area*MolecularWeight/Sum(Average area*MolecularWeight)). Finally, the fold increase of each protein amount in Bvg+ vs. Bvg- and Bvg- vs. Bvg+ is reported together with 
the PSORTb and DOLOP prediction of subcellular localization.  
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Vaccine antigen selection 
We applied two main criteria for antigen selection: putative antigens should be either 
Bvg+ exclusive or showing at least a 2.5 fold increase as compared to Bvg- and they 
should have a predicted outer membrane localization according to PSORTb. The list of 
the resulting selected antigens is reported in Table 3. Based on their high abundance in 
OMV (each higher than 1% of total protein amount) and excluding the proteins already 
part of the currently available aP formulation, we focused on six promising candidates 
to be assessed for their adhesive properties and vaccine potential: BrkA, Vag8, TcfA, 
SphB1, BipA and BfrD. Interestingly, five of the selected antigens had a predicted 
autotransporter structure. 
 
 
Table 3. OMV-based antigen selection. Antigens were selected from the total proteins quantified in 
OMV based on the following criteria: Bvg regulation, localization prediction and abundance. Percentages 
refer to the total protein composition of OMV from either Bvg+ or Bvg- phase averaged between the two 
biological replicates. 
#
 known B. pertussis protective antigens *=antigen selected for further analysis, 
§
=antigen currently included in a commercial vaccine. 
Accession Protein name   % Bvg+ % Bvg- 
NP_880571.1 FHA filamentous hemagglutinin/adhesin
§#
 16,64% 0,01% 
NP_882013.1 BrkA autotransporter*
#
 11,82% 0,04% 
NP_879839.1 Prn Pertactin autotransporter
§#
 8,46% 0,00% 
NP_879104.1 SphB1 autotransporter subtilisin-like protease*
#
 6,50% 0,00% 
NP_880953.1 Vag8 autotransporter*
#
 4,72% 0,00% 
NP_879974.1 TcfA tracheal colonization factor*
#
 3,77% 0,00% 
NP_879893.1 BipA outer membrane ligand binding protein*
#
 3,42% 0,74% 
NP_879666.1 BfrD TonB-dependent receptor* 1,48% 0,01% 
NP_880575.1 FhaC filamentous hemagglutinin transporter protein  0,66% 0,07% 
NP_879378.1 BP0529 autotransporter 0,36% 0,02% 
NP_881933.1 OmpQ outer membrane porin protein 0,08% 0,00% 
NP_881280.1 Adhesin FhaS  0,08% 0,01% 
NP_880573.1 FimC outer membrane usher protein  0,07% 0,00% 
NP_880879.1 Type III secretion protein 0,04% 0,00% 
NP_879314.1 Heme receptor HemC 0,03% 0,00% 
NP_880296.1 Exported protein BP1561 0,01% 0,00% 
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Recombinant E. coli strains adhesion and adhesion inhibition assays 
In order to evaluate the adhesive properties of each single protein we exploited E. coli 
as an heterologous background system for surface exposure of the selected antigens. We 
generated E. coli strains constitutively expressing the selected full length proteins and 
checked for their ability to bind to A549 respiratory epithelial cells as compared to wild 
type E. coli. A549 cells were infected with E. coli strains for three hours, then washed 
to remove unbound bacteria, fixed and stained with an anti-E. coli antibody. We found 
that BrkA, SphB1, Vag8 and TcfA conferred adhesive ability to E. coli when expressed 
on the membrane. On the contrary, heterologous expression of BipA and BfrD had no 
effect on strain adhesiveness (Fig. 5A). We continued the analysis by testing if the E. 
coli strains singularly expressing the selected antigens were detected with the anti-OMV 
serum we had generated. By flow cytometry, anti-OMV serum was able to recognize 
the specific heterologously expressed BrkA, Vag8 and BipA (Fig. 5B). This result 
proved not only that BrkA, Vag8 and BipA antibodies had been elicited after mice 
immunization with B. pertussis OMV but also that these proteins are properly expressed 
and surface-exposed on E. coli. Finally, to determine whether the inhibition of B. 
pertussis adhesion promoted by anti-OMV serum correlated with the presence of 
specific antibodies against the selected antigens we tested its inhibitory effect on the 
adhesion of recombinant E. coli strains. We found that anti-OMV serum caused 
reduction of adhering E. coli at high serum concentration only when BrkA was 
expressed on the bacterial surface. Unexpectedly, Vag8-expressing E. coli was not 
inhibited despite the presence of specific anti-Vag8 antibodies in the serum (Fig. 5C). 
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FIG. 5. Functional and immunological 
characterization of the selected antigens 
heterologously expressed on E. coli. A. Adhesion of 
recombinant E. coli strains on A549 cells. A549 cells 
were infected with bacteria for 3 hours. Cell-associated 
bacteria were quantified by fluorescence reading after 
staining with a rabbit anti-E. coli antibody. Results 
represent mean ± SD of one representative of three 
independent experiments each performed in triplicates, 
****=P < 0.0001, ns= non-significant. B. FACS 
analysis on recombinant E. coli strain with anti-OMV 
serum: recombinant E. coli strains were collected in 
early exponential phase, stained with mouse anti-OMV 
antibody and finally fixed with 3.7% formaldehyde. 
Recognition of surface exposed B. pertussis antigens 
was checked by flow cytometry using FACS Canto II flow cytometer (BD Biosciences). C. Impact of anti-OMV serum on E. coli adhesion to A549 cells: anti-OMV serum was 
serially diluted in infection medium and incubated with recombinant E. coli strains for 1 h. A549 cells were then infected with the bacteria/sera mixtures for 3 hours and cell-
associated bacteria were quantified by fluorescence reading. Results represent mean ± SD of one representative of three independent experiments each performed in triplicates. 
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Recombinant BrkA protein production and vaccination 
To analyze the protective potential of BrkA, recombinant His-tagged protein was 
expressed, purified and used to immunize mice three times, four weeks apart. Fifteen 
days after the final vaccination, mice were challenged with aerosolized B. pertussis and 
seven days later the bacterial load in the lungs was evaluated by CFU counting. This 
experiment showed that immunization with recombinant BrkA resulted in about 100 
fold reduction of bacterial load in the lung as compared to control mice treated with 
adjuvant only (Fig. 6).  
 
FIG. 6. Protection induced by BrkA in the mouse B. pertussis aerosol challenge model: B. pertussis 
infection was followed by performing CFU counts on lungs from groups of 10 mice seven days after 
aerosol challenge. Protection is reported as compared to mice immunized with the adjuvant only. Results 
represent mean ± SD; ****=P < 0.0001. 
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2.2 Discussion and conclusions 
The increase in pertussis outbreaks and the recent observations with the employment of 
the baboon model for pertussis infection clearly indicated that a more potent vaccine is 
needed to prevent not only the disease but also the colonization and therefore 
transmission of the bacterium. The control of the bacterial burden is governed by 
multiple mechanisms leading to bacterial killing and interference to the infection 
process. Among them, the presence of functional antibodies at the epithelial barrier able 
to target key adhesins is a valuable countermeasure to inhibit the attachment of bacteria 
and initiation of colonization. In this study, we used outer membrane vesicles to identify 
potential novel antigens with adhesive properties. Indeed, OMV mainly contain outer 
membrane proteins and lipoproteins in the membrane bilayer and periplasmic proteins 
in their lumen. Aiming at preventing B. pertussis colonization of the human respiratory 
tract, we checked the ability of anti-OMV serum to inhibit B. pertussis adhesion on 
A549 respiratory epithelial cells. Interestingly, anti-OMV serum proved to be 
particularly powerful in preventing B. pertussis adhesion to respiratory epithelial cells. 
Clearly, the whole inhibitory effect on bacterial adhesion is likely determined by the 
additive effects of different antibodies targeting various antigens displayed by OMV 
and present on B. pertussis surface. We therefore decided to deepen the analysis at the 
single protein level, looking for proteins present in OMV that could elicit anti-adhesive 
antibodies after immunization. The comparative proteomic analysis between OMV from 
Bvg+ and Bvg- allowed the identification and quantification of over two hundred 
proteins and showed that ~58% of proteins quantified in Bvg+ OMV are specific for 
that phase and their amount drops to ~0,1% in Bvg- OMV. This finding is in agreement 
with the well-established regulation of the virulence genes by the BvgAS two-
component system in B. pertussis. Interestingly, among the 23 Bvg+ specific proteins, 
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10 proteins were predicted to be outer membrane proteins and represented ~53% of the 
total Bvg+ OMV protein amount. Among the Bvg+ specific proteins we found the best 
known and characterized B. pertussis adhesins such as FHA, 69K and Fimbriae together 
with Pertussis Toxin. On the contrary, Adenylate Cyclase Toxin and Dermonecrotic 
Toxin were not identified. On the other hand, the majority of Bvg- specific proteins 
appeared to be cytoplasmic contaminants, possibly indicating that B. pertussis strain 
BP537 is more prone to lyse during growth. Finally, among the proteins that did not 
result to be specific for one or the other phase, the analysis showed a slightly increased 
amount of lipoproteins, outer membrane and periplasmic proteins in Bvg- OMV vs. 
Bvg+ OMV. Therefore, it is tempting to hypothesize that most of the proteins in Bvg- 
OMV are overrepresented to compensate for the lack of the Bvg+ outer membrane 
proteins and the outer membrane porin protein BP0840 perfectly supported this 
hypothesis, resulting to be the most abundant protein in Bvg- OMV and representing 
~20% of the total protein amount as compared to ~2.5% in Bvg+ OMV. The NTA 
analysis further supported the hypothesis of a compensative mechanism, showing no 
differences in size distribution and quantity of proteins per vesicle in both OMV 
samples. The protein composition of OMV described in the present study differs 
substantially from what has been shown in a previous report (Raeven, van der Maas et 
al. 2015). While the high quantity of BrkA and Vag8 is confirmed in both studies, the 
overall composition in terms of presence and relative abundance is drastically different. 
This is likely due to the distinct OMV purification methods and B. pertussis strains 
employed in the two studies. The proteomic analysis presented in this study allowed the 
identification of an initial list of putative antigens, which were narrowed down to 16 
interesting candidates: this first antigen selection resulted in seven known B. pertussis 
protective antigens including two of the current aP antigens, thus validating our strategy 
to identify virulence factors. It is intriguing to underline that proteomic analysis of two 
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currently circulating B. pertussis strains under in vitro Bvg+ and Bvg- conditions (de 
Gouw, de Jonge et al. 2014), combined to in silico prediction for surface- expression, 
resulted in a panel of top 15 candidates which perfectly mirrors the OMV-based antigen 
selection described in our study. Then, albeit with variations in the strains and methods 
employed, the membrane composition of OMV seems to closely reflect the composition 
of whole bacteria. We decided to focus our attention on the most abundant Bvg+ outer 
membrane proteins and interestingly five autotransporter proteins were at the top of our 
list. Autotransporters are possibly the simplest bacterial secretion systems (type V): they 
consist only of a single polypeptide chain organized in a passenger and translocator 
domain and they have the ability to autonomously translocate across the outer 
membrane (Fan, Chauhan et al. 2016). Therefore, the heterologous expression of the 
autotransporters on the surface of E. coli was selected to characterize their adhesive 
properties. This approach allowed the demonstration that BrkA, TcfA, SphB1 and Vag8 
conferred to E. coli a significant increased ability to adhere to lung epithelial cells. To 
the best of our knowledge, this is the first time that B. pertussis autotransporters were 
rationally characterized for their adhesive properties exploiting a heterologous E. coli 
background. The involvement in adhesion of BrkA was previously demonstrated in in 
vitro analysis and in mouse infection studies with B. pertussis mutant strains showing 2-
fold and 2-log reduction in the ability to adhere to cell lines and to colonize the murine 
lungs, respectively (Fernandez and Weiss 1994, Elder and Harvill 2004). Also, the loss 
of TcfA was previously shown to cause 10-fold reduction in the number of bacteria 
isolated from tracheas after B. pertussis aerosol challenge (Finn and Stevens 1995). 
Nevertheless, deletion of individual virulence factor genes could have limited effects on 
the ability of B. pertussis to efficiently infect the respiratory tract of mice, suggesting 
they may perform redundant functions. This was the case of a Vag8 deletion mutant, 
which was as efficient as the parental B. pertussis strain in colonizing murine lungs 
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(Finn and Amsbaugh 1998). On the contrary, our study proved that Vag8 is also 
involved in adhesion and not only in serum resistance as previously described (Marr, 
Shah et al. 2011). In other cases, the generation of single knock-outs could be 
misleading. In fact, SphB1 loss has an indirect effect on Filamentous Hemagglutinin 
which is not cleaved anymore from B. pertussis surface therefore rendering the mutant 
strain even more adhesive than the wild-type parental strain (Coutte, Alonso et al. 2003) 
but in this study we showed that SphB1 itself can contribute to the overall adhesiveness 
of B. pertussis. Two of the heterogously expressed antigens, BipA and BfrD, did not 
confer an adhesive phenotype to E. coli. While this result could be expected for BfrD, 
which is reported to be involved in iron acquisition (Brickman, Suhadolc et al. 2015), it 
was quite controversial for BipA, which is partially characterized in the literature as the 
major adhesin in the intermediate phase between Bvg+ and Bvg- (Stockbauer, 
Fuchslocher et al. 2001). This particular virulence phase (Bvg
i
) was described to be 
involved in the transmission of B. pertussis from host to host and a BipA deletion 
mutant of a Bvg
i
-locked B. pertussis strain displayed a reduced ability to colonize the 
nasal cavity of mice compared with the parental strain (Vergara-Irigaray, Chavarri-
Martinez et al. 2005). BipA was also identified as the most abundant surface-associated 
biofilm protein (de Gouw, Serra et al. 2014) therefore it is likely involved in bacterium-
bacterium interactions as well as host-pathogen interactions. Our results were in 
contrast with the previous reports but, in the absence of specific antibodies, we could 
not rule out that BipA is not properly expressed and surface exposed on E. coli. We 
therefore took advantage of sera raised against OMV to explore whether the 
heterologously expressed antigens were recognized on the surface of E. coli. Only three 
proteins, BrkA, Vag8 and BipA, were specifically recognized on E. coli surface by anti-
OMV serum, thus excluding the possibility that BipA was not properly surface-exposed 
on the outer membrane. Finally, we checked the ability of anti-OMV serum to inhibit 
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recombinant E. coli adhesion to lung A549 cells. The inhibitory effect of anti-OMV 
serum was only observed on the adhesion of BrkA-expressing E. coli, demonstrating the 
functionality of anti-BrkA antibodies. Consistently with the fact that SphB1 and TcfA-
expressing E. coli strains were not recognized by anti-OMV serum, no inhibition was 
observed on the adhesiveness of these strains. On the contrary, anti-OMV serum was 
not able to inhibit Vag8-expressing E. coli strain; whether this is due to low antibodies 
level or to weak antibody functionality needs further clarification. As far as BfrD is 
concerned, it did not result to have a contribution in adhesion nor to be recognized by 
anti-OMV serum on E. coli surface, therefore was excluded from the adhesion 
inhibition assay. Still, given its predicted structure of integral outer membrane protein, 
we cannot exclude that it is not properly expressed on the surface of E. coli. The FACS 
analysis using anti-OMV serum on E. coli strains also gave us an indirect result on the 
ability of the selected antigens to be immunogenic in the context of OMV. 
Immunization of mice with OMV results in a wide antibody repertoire somehow 
reflecting what happens during a natural infection with B. pertussis or during a 
vaccination with wP. Clearly, in the density of the OMV lipid bilayer, some abundant 
proteins might not induce that high antibody response, whereas some less abundant 
proteins might be immuno-dominant and induce higher responses. While the presence 
of anti-BrkA, anti-Vag8 and anti-BipA antibodies correlated with high abundance of 
these proteins on OMV (around ~12%, ~5% and ~3% respectively), the absence of anti-
SphB1 and anti-TcfA antibodies was unexpected given the high quantity of these 
proteins on vesicles (around ~6% and ~4% respectively). Nevertheless, immunization of 
mice with recombinant proteins could have a completely different outcome and elicit 
specific anti-adhesive antibodies, as previously demonstrated. Indeed, the protective 
role of autotransporters is a peculiar trait of B. pertussis and thus far, five 
autotransporters have shown to confer protection in the mouse model (either aerosol or 
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intranasal challenge) when expressed as recombinant proteins, including Prn (Roberts, 
Tite et al. 1992), TcfA (Sukumar, Love et al. 2009), SphB1 (de Gouw, de Jonge et al. 
2014), Vag8 (de Gouw, de Jonge et al. 2014) and BipA (de Gouw, Serra et al. 2014) 
suggesting that B. pertussis evolved this class of proteins as virulence strategy to 
colonize the host. Here, we demonstrated that immunization with recombinant BrkA 
resulted in significant protection against lower respiratory tract infection of B. pertussis 
in the mouse aerosol challenge model. This was different with respect to what 
previously reported using the mouse intranasal challenge model, where BrkA resulted 
as an added value only when formulated with aP and not as stand-alone vaccine (Marr, 
Oliver et al. 2008); however the two studies differ both in the immunization route and in 
the bacterial infection administration. Finally, we contributed to unravel the mechanism 
of protection induced by anti-BrkA antibodies showing the inhibitory properties against 
the bacterial adhesion. In conclusion, BrkA proved to be a promising candidate antigen 
to improve existing aP vaccines for use in humans. Whether such multi-component aP 
vaccines that include BrkA and possibly further virulence factors of B. pertussis other 
than Pertussis Toxin, Filamentous Hemagglutinin, Pertactin and Fimbriae have superior 
efficacy over existing aP vaccines remains to be determined.  
Taken together, this study suggests that spontaneously released OMV from B. pertussis 
provide a potential source of protective antigens able to specifically target the 
colonization step. The inclusion of BrkA and possibly further adhesins may provide a 
higher protection to current aP vaccines answering to the need of improving the impact 
of vaccination on the bacterial clearance. 
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3. Chapter two: contribution of naturally released 
Outer Membrane Vesicles from Bordetella pertussis to 
bacterial physiology and pathogenesis 
Bordetella pertussis has been shown to release OMV both in vitro and in vivo; these 
vesicles are widely characterized for their immunogenic and protective properties as 
vaccine candidates but little information is available about the functional roles of B. 
pertussis OMV during respiratory tract infection (Hozbor, Rodriguez et al. 1999, 
Roberts, Moreno et al. 2008, Asensio, Gaillard et al. 2011, Bottero, Gaillard et al. 2013, 
Ormazabal, Bartel et al. 2014, Bottero, Gaillard et al. 2016). Previously, Donato et al. 
showed cell intoxication following OMV treatment and suggested that B. pertussis 
could release OMV as an alternative delivery system for the Adenylate Cyclase Toxin 
to target cells and increase intracellular cyclic-AMP (Donato, Goldsmith et al. 2012). 
Nevertheless, the delivery of virulence factors to host cell is just one of the many 
functions that make OMV an important player in the physiology of Gram-negative 
bacteria. In this study, we investigated the interaction between purified vesicles and host 
cells and we were able to show that OMV binding and uptake by different cell lines is 
strictly related to the bacterial virulent phase and contributes to host cell intoxication. 
Also, we explored a new putative role for OMV as iron scavengers, reservoirs and 
delivery systems and proved that they are able to complement B. pertussis growth 
defects in iron-limiting conditions. 
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3.1. Results and discussion 
OMV are naturally released during B. pertussis infection of a primary ciliated 
epithelium 
While the release of OMV during in vitro growth is largely defined and is a common 
feature of Gram-negative bacteria, less described is the production of OMV in 
physiological conditions during the natural infection. Previously, B. pertussis organisms 
with associated OMV were shown through electron microscopy on lung sections from a 
fatal case of whooping cough. To demonstrate whether OMV are released during the 
initial phases of B. pertussis colonization of the upper respiratory tract we studied the 
interaction of B. pertussis with highly differentiated human bronchial epithelial cells 
(NHBE cells). These cells, grown at air-liquid interface, express the mucociliary 
structures typical of the human airways, offering a physiological model to study the 
early stage of B. pertussis infection. Indeed, this model proved to very well reproduce 
the temporal and spatial stages of adhesion of B. pertussis on primary ciliated cells 
(Guevara, Zhang et al. 2016). NHBE cells were incubated with B. pertussis BP536 
strain and then analyzed by scanning electron microscopy. As shown in Figure 7, 
following three days incubation, B. pertussis was able to form micro-colonies on 
ciliated cells and to be associated with large amounts of blebs supporting the hypothesis 
that OMV could play a role in host-pathogen interaction.  
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FIG. 7. Bordetella pertussis infection of a normal human bronchial epithelium. Scanning electron microscopy of Normal Human Bronchial Epithelial (NHBE) cells 
differentiated in air-liquid interphase infected with B. pertussis. B. pertussis is able to form micro-colonies on ciliated cells after three days and releases large amounts of outer 
membrane vesicles. Dashed box’s magnification is reported on the right. 
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Only OMV released by B. pertussis in Bvg+ phase interact  
with respiratory epithelial cells 
In the perspective of studying the interaction of native OMV with host cells, we 
optimized the protocol for OMV isolation to preserve as much as possible their native 
features. Different methods for OMV purification from B. pertussis bacterial cells or 
culture supernatant were previously described but these protocols were optimized in a 
vaccine perspective rather than for functional studies (Hozbor, Rodriguez et al. 1999). 
For example, the use of detergents like sodium deoxycholate to extract vesicles from 
bacterial cells or treatment of cell-free culture supernatants with glutaraldehyde results 
in high yields of OMV but could alter the native conformation of proteins in the 
vesicles. In the present study, the naturally produced OMV were purified from culture 
supernatants through ultracentrifugation avoiding any chemical treatment that could 
alter their intrinsic nature.  
Purified OMV were studied for their interaction with host cells. Given that Bvg-
activated proteins are mainly associated with colonization and toxicity, OMV were 
isolated from B. pertussis strains BP536 (Bvg+ phase) and BP537 (Bvg- phase) 
(Decker, James et al. 2012) and analyzed for their ability to bind to A549 and Calu-3 
epithelial cells. Cells were incubated with OMV derived from the two Bvg+ and Bvg - 
strains up to six hours, and analyzed at different time points by immuno-staining and 
plate reading of OMV-associated fluorescence. As shown in Figure 8A, only Bvg+ 
OMV were able to bind to A549 cells and Calu-3 cells in a time-dependent manner 
reaching saturation after 6 hours. The evidence that OMV purified from the avirulent 
strain BP537 are not able to bind A549 or Calu-3 cells suggests that Bvg-activated 
virulence factors are responsible for the first attachment of OMV to the membrane of 
host cells. This in agreement with what known for other pathogens, in which the key 
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virulence factors are also involved the interaction of bacterial vesicles to host cell 
(Fiocca, Necchi et al. 1999, Kesty, Mason et al. 2004, Chatterjee and Chaudhuri 2011). 
To verify whether B. pertussis best known adhesins, Filamentous Hemagglutinin (FHA) 
and Pertactin (69K), had a role in OMV adhesion to epithelial cells, OMV purified from 
isogenic B. pertussis knock-out strains were analyzed for their adhesive properties. As 
shown in Figure 8B, the adhesive properties of OMV depleted of 69K and FHA were 
not different from that of OMV derived from the wild-type strain suggesting that this 
two antigens have no key role in the adhesion of OMV to epithelial cells. This finding 
was unexpected, considering the primary contribution that has been reported for the two 
adhesins in the bacterial adhesion on A549 cells (Zanaboni, Arato et al. 2016). Overall 
these data suggest that bacteria and their vesicles could use different adhesive molecules 
to interact with epithelial cells and that the differential binding can result in a synergistic 
rather than a competitive effect during host-pathogen interaction.  
Internalization of OMV was qualitatively assessed by confocal and electron 
microscopy: intracellular localization was mainly perinuclear in A549 cells incubated 
with OMV for 6 hours and stained with anti-OMV mouse serum (Fig. 9A). In order to 
better validate the internalization process we decided to employ the more complex and 
physiological cell model of polarized Calu-3 cells. Indeed, highly polarized epithelial 
cells are characterized by distinct apical and basolateral plasma membrane domains and 
by specialized intracellular trafficking machinery which make them more suitable for 
internalization studies. Interestingly, when polarized Calu-3 cells were analyzed for 
OMV binding and internalization by electron microscopy, we were able to show that 
multiple OMV bind and are subsequently internalized in the same intracellular 
compartment (Fig. 9B).  
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FIG. 8. Interaction between B. pertussis OMV and human respiratory epithelial cells. (A) Cells were 
infected with OMV and, after extensive washes to remove unbound vesicles, cells were fixed and stained 
with mouse anti-OMV primary antibody and with AlexaFluor488-conjugated anti-mouse secondary 
antibody. Cell-associated OMV were quantified by fluorescence reading at Ex/Em 485/535 nm. Results 
represent mean ± SD of one representative of three independent experiments each performed in triplicates, 
****=P < 0.0001. (B) OMV were purified from B. pertussis strain BP536 and from isogenic knock-out 
strains for FHA and 69K. Cell-associated OMV were quantified by fluorescence reading at Ex/Em 
485/535 nm. Results represent mean ± SD of one representative of three independent experiments each 
performed in triplicates, ns= non-significant. Western blot analyses were performed according to standard 
procedures. FHA and 69K were identified with polyclonal mouse antisera raised against the purified 
proteins (diluted 1:1000). 
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FIG. 9. B. pertussis OMV internalization by human respiratory epithelial cells. (A) Confocal microscopy analysis of OMV uptake by A549 cells. A549 cells were incubated 
with 10 ng/µL of OMV purified from BP536 (Bvg+) and stained with a primary mouse polyclonal anti-OMV serum and secondary fluorescent antibody (green staining). Actin 
was stained with Phalloidin-568 dye (red staining) and nuclei with DAPI (blue staining). (B) Transmission Electron Microscopy analysis of OMV uptake by polarized Calu-3 
cells. Calu-3 cells were incubated with 10 ng/μL of OMV purified from BP536 (Bvg+) then fixed and prepared for TEM analysis. 
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OMV-associated Pertussis Toxin (PT) is able to promote cell intoxication 
We explored whether OMV could contribute to B. pertussis pathogenesis by delivering 
toxins to host cells. Several toxins have been described as associated with OMV 
(including Cholera Toxin, Heat Labile Enterotoxin, VacA, Shiga Toxin) and they 
exploit the vesicles as an additional delivery system for cell intoxication processes. We 
employed a proteomic approach to quantify all the proteins in OMV deriving from 
bacteria in the virulent phase and we found that Pertussis Toxin was present in OMV, 
representing about 0.45% of the total protein composition. On the contrary, Adenylate 
Cyclase Toxin (ACT) and Dermonecrotic Toxin, also known to be secreted, were not 
present among the OMV components. The absence of ACT in the naturally released 
vesicles confirmed what already described in two different studies carried-out on OMV 
purified by ultracentrifugation or ultrafiltration of culture supernatants (Hanawa, 
Yonezawa et al. 2013, Raeven, van der Maas et al. 2015). These evidences were instead 
in contrast with what published in previous studies reporting the presence of ACT in 
OMV (Hozbor, Rodriguez et al. 1999) and cell intoxication detected as cAMP increase 
attributed to the presence of ACT as OMV cargo (Donato, Goldsmith et al. 2012). 
These discrepancies are likely imputable to variations in the method employed for 
OMV isolation; a deoxycholate extraction (Donato, Goldsmith et al. 2012) or a 
glutaraldehyde treatment (Hozbor, Rodriguez et al. 1999) were performed before 
ultracentrifugation to increase OMV yields but these chemical agents could alter the 
native protein composition of the vesicles and favor unwanted membrane-fixing of 
some proteins.  
At first, we confirmed the presence of PT through western blot analysis on OMV (Fig. 
10A), including BP536 OMV (a Bvg+ phase strain expressing PT), BP537 OMV (a 
Bvg- phase strain not expressing PT) and W28 PT9K/129G OMV (a Bvg+ strain 
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expressing a genetically detoxified PT). Subsequently, to verify the toxicity potential of 
OMV-associated PT, we tested the ability of the OMV to cause cell clustering in CHO 
cells. CHO cells were incubated with OMV at concentrations ranging from 160 to 20 
g/ml. As shown in Figure 10B, only OMV derived from a wild-type strain were able to 
induce CHO cell clustering and the minimal OMV concentration inducing cell 
intoxication was 40 g/mL. As expected, OMV from a strain expressing genetically 
detoxified PT (W28 PT9K/129G) did not show a toxic activity. The active PT in the 
soluble form was included in the experiment as positive control and the minimal dose 
needed to cause 100% cell clustering was 2 ng/mL. Although we performed a 
quantification of the PT associated to OMV by proteomic analysis, the extrapolation of 
the minimal OMV concentration needed for intoxication remains questionable. The 
amount of vesicles entering the cells is not predictable and the accessibility or 
functionality of the PT associated to OMV could differ from its secreted form. These 
data indicate that the PT packed in OMV is biologically active and could have a 
synergistic effect with its secreted form during the dissemination to host cells.Whether 
the presence of PT in the OMV is due to an accumulation in the periplasm or to a re-
association through interactions with other outer membrane proteins or LPS remains to 
be determined. Also, further studies must be conducted to determine the mechanism by 
which PT is internalized by host cells via OMV and understand the mutual contribution 
of soluble versus OMV-associated PT during the pathogenesis processes.  
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FIG.10. Citotoxicity mediated by OMV-associated PT. A. Presence of PT on OMV. Western blot 
analyses were performed according to standard procedures. PT was identified with a mouse monoclonal 
antibody targeting the S1 subunit of the toxin (diluted 1:200). B. CHO cells clustering assay. OMV from 
BP536 and W28 PT9K/129G (genetically detoxified PT) were added to CHO-K1 cells (2x105cells/ml) 
and incubated for 16 hours at 37°C in 96-well plates. PT-mediated toxicity was evaluated by observation 
of morphological alterations (clustered phenotype) by light microscopy. Purified PT (2 ng/mL) was used 
as positive control. Reported is the treatment with the lowest concentration of OMV inducing cell 
clustering (40 µg/mL). 
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OMV have a role in iron delivery 
There are growing evidences supporting the role for OMV in the delivery of nutrients of 
interest to bacterial cells (Evans, Davey et al. 2012, Toledo, Coleman et al. 2012, Biller, 
Schubotz et al. 2014). In particular, OMV have been described to promote iron 
acquisition in bacterial communities (Dashper, Hendtlass et al. 2000, Smalley, Byrne et 
al. 2011, Prados-Rosales, Weinrick et al. 2014). Of interest, a proteomic analysis of B. 
pertussis OMV revealed the presence of a high number of proteins involved in iron 
uptake and storage (Table 4). 
Protein # Gene # Gene name 
NP_879666 BfrD (BP0856) TonB-dependent receptor BfrD 
NP_881504 BfrG (BP2922) TonB-dependent receptor BfrG 
NP_881648 BP3077 Outer membrane protein 
NP_880337 BP1605 Iron binding protein 
NP_879667 BfrE (BP0857) TonB-dependent receptor for iron transport 
NP_879314 HemC (BP0456) Heme receptor 
Table 4. Iron receptors and iron binding proteins identified by LC-MS/MS 
Clearly, this hypothesis implies that OMV are able to capture iron and deliver it back to 
the bacteria; thus far, this was demonstrated only for Mycobacterium tuberculosis 
membrane vesicles (Prados-Rosales, Weinrick et al. 2014). We therefore checked if 
OMV were able to complement the growth defects of B. pertussis in iron-limiting 
conditions (Fig. 11). If no FeSO4 is supplemented in the culture media, B. pertussis is 
still able to grow at slower rate and it reaches stationary phase at a lower optical density. 
Interestingly, if exogenous OMV, here termed “loaded OMV”, were added in the 
culture media, they were able to restore B. pertussis regular growth. This did not occur 
using OMV purified from B. pertussis cultured in the absence of FeSO4 (“empty 
OMV”). Contrarily to what reported for M. tuberculosis, iron starvation does not induce 
vesicle hyperproduction in B. pertussis.  
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FIG. 11. B. pertussis growth under iron-limiting conditions and contribution of OMV to iron 
delivery. B. pertussis strain BP536 was cultured in Steiner-Sholte medium either supplemented or not 
with FeSO4, in combination with OMV purified from BP536 or BP537 cultures in the presence (“OMV 
loaded”) or absence (“OMV empty”) of FeSO4. Error bars represent standard deviations from the means 
of biological triplicates.  
To understand whether OMV were already loaded with iron when released from the 
bacteria or whether they loaded it after their release in the external milieu, OMV were 
purified from an iron-limited culture supernatant and were subsequently incubated at 
37°C overnight with 10 µg/mL of FeSO4 (“reloaded OMV”). OMV were then purified 
by ultracentrifugation and washed with D-PBS to remove any excess of FeSO4. As 
shown in Figure 12, OMV have the intrinsic ability to load iron independently to the 
presence of bacterial cells; indeed the so termed “reloaded OMV” reacquired the ability 
to restore B. pertussis regular growth in the absence of FeSO4 in the culture media. 
Opposite to what we observed for the interaction with host cells, this mechanism 
seemed to be independent of the Bvg regulation; indeed, we obtained comparable 
results using OMV purified from BP536 or BP537 cultures.  
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FIG. 12. Iron acquisition by purified B. pertussis OMV. B. pertussis strain BP536 was cultured in 
Steiner-Sholte medium either supplemented or not with FeSO4, in combination with OMV purified from 
BP536 or BP537. Previously, purified OMV were incubated at 37°C overnight either with H20 (“empty 
OMV”) or with 10 µg/mL of FeSO4 (“reloaded OMV”) then washed with D-PBS, ultracentrifuged at 
175,000 x g for 2 hours and finally re-suspended in 100µl D-PBS. Error bars represent standard 
deviations from the means of three biological replicates. ****=P < 0.0001, ns= non-significant. 
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3.2 Conclusions 
In conclusion, our results suggest that the release of outer membrane vesicles from B. 
pertussis is a physio-pathological event that occurs starting from the very early stages of 
infection of the human respiratory epithelium. Purified vesicles can associate with 
human lung cells and can be internalized in a time-dependent manner reaching the 
perinuclear region of the host cells. Many questions remain concerning OMV 
trafficking and fate after endocytosis and further experiments will be necessary to 
ultimately identify the host cell and the bacterial factors critical for B. pertussis OMV 
entry. As far as the protein cargo is concerned, PT is the only toxin identified in Bvg+ 
OMV and it was shown to be functional in the CHO cell clustering assay. Clearly, 
OMV uptake is not the primary pathway for PT delivery but it may provide an 
important supplemental mechanism for B. pertussis intoxication of host cells and 
contribute to the inflammatory response during infection, acting synergistically with the 
all the other secreted toxins. On the other hand, vesicles were shown to function as iron 
reservoirs and to interact with bacterial cells to deliver the vital metal. Such an 
involvement of OMV in iron acquisition might be extremely important in the context of 
infection. Indeed, iron is an essential factor for nearly all organism and bacteria have 
evolved different mechanisms to obtain it in the host environment. B. pertussis was 
shown to bind to ciliated cells and to form micro-colonies and biofilm while OMV are 
certainly more readily diffusible and able to cover larger areas. This study lays the basis 
for the understating of a novel mechanism of B. pertussis physio-pathology to be further 
characterized at the molecular level.    
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4. Experimental procedures 
4.1. Bacterial strains and growth conditions 
B. pertussis strains used in this study are reported in Table 5. Bacteria were stored at 
−80 °C and recovered by plating on Bordet-Gengou (BG) agar plates, supplemented 
with 15 % sheep blood, for 3 days at 37 °C. Bacteria were then inoculated at initial 600 
nm optical density (OD600) of 0.05 in Stainer-Scholte medium supplemented with 0.4 
% (w/v) L-cysteine monohydrochloride, 0.1 % (w/v) FeSO4, 0.2 % (w/v) ascorbic acid, 
0.04 % (w/v) nicotinic acid, 1 % (w/v) glutathione. Cultures were grown in rotary 
shakers at 37 °C. 
Strain Description Reference 
BP536 BP338 Bvg+; StrepR (Weiss and Falkow 1983) 
BP537 BP536 Bvg-; StrepR (Relman, Domenighini et al. 1989) 
BP-102 BP536 Δ(3.4 kb BamHI-BglII)fhaB; FHA- (Arico, Nuti et al. 1993) 
BP-BBC42 BP536 prn::KanR; PRN- (Arico, Nuti et al. 1993) 
W28 9K/129G StrepR, genetically detoxified PT (Pizza, Covacci et al. 1989) 
Table 5. Bordetella strains used in this study. 
Recombinant DH5α E. coli strains were stored at −80 °C, recovered by plating on LB 
agar plates supplemented with 20 μg/mL chloramphenicol for 16 hours at 37 °C. For 
liquid cultures, bacteria were inoculated in LB medium supplemented with 20 μg/mL 
chloramphenicol and were grown in rotary shakers at 37 °C for 16 hours. 
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4.2. Generation of E. coli strains expressing heterologous 
antigens 
E. coli strain DH5α was transformed with a range of 6 plasmids based on the broad host 
range vector pMMB208 (Morales, Backman et al. 1991) which was modified to express 
the candidate adhesins. The ApaI-XbaI fragment containing the lacI gene and the IPTG-
inducible pTac promoter was substituted with an expressing cassette consisting of a 
constitutive B. pertussis promoter and the full length coding sequences for brkA, sphB1, 
vag8, tcfA, bipA and bfrD. The promoter and the coding sequences were amplified from 
B. pertussis W28 9K/129G genomic DNA using the primers reported in Table 6. The 
amplified promoter fragment was digested with ApaI/HindIII and the amplified CDS 
were digested with HindIII/XbaI and were ligated into the ApaI-XbaI digested vector 
and the final constructs were checked by sequencing. The plasmids were transformed 
into E. coli DH5α and stored at -80 °C.  
Primer name Sequence 
pBP0840 Forward cccGGGCCCTCCTTGAGTGAACTGGGGG 
pBP0840 Reverse cccAAGCTTAATCTCCGTTGATTTGAGTGA 
brkA Forward cccAAGCTTATGTATCTCGATAGATTCCGTCAA 
brkA Reverse cccTCTAGATCAGAAGCTGTAGCGGTAGC 
sphB1 Forward cccAAGCTTGTGATGCCGCCGCCGGCCGT 
sphB1 Reverse cccTCTAGATCAGTAGCGGTAAGTGAGGCT 
vag8 Forward cccAAGCTTATGGCAGGACAAGCGAGG 
vag8 Reverse cccTCTAGATCACCAGCTGTAGCGATACC 
tcfA Forward cccAAGCTTATGCACATTTACGGAAATATGAA 
tcfA Reverse cccTCTAGACTACCAGGCGTAGCGATAGC 
bipA Forward cccAAGCTTATGAACAAGAACATTTACCGTGTT 
bipA Reverse cccTCTAGATTAGTAAGGAAAATTGACCGGC 
bfrD Forward cccAAGCTTATGAAGTTCTACTCTTCCCATCC 
bfrD Reverse cccTCTAGATCAGTAGCTCAGCTTGAACGTC 
Table 6. List of primers used in this study 
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4.3. Cell lines and growht conditions 
The human alveolar epithelial cell line A549 (human lung type II pneumocyte) (ATCC 
CCL185) was cultured in F12K medium (Invitrogen) supplemented with 10% of fetal 
bovine serum (FBS), 100 U mL−1 penicillin, and 100 mg mL−1 streptomycin (Sigma) 
at 37 °C in 5% CO2. Routine subcultures for A549 pneumocytes were performed at 1:3 
split ratios by incubation with 0.05% trypsin-0.02% EDTA for 5 min at 37 °C.  
The human airway epithelial cell line Calu-3 (ATCC HTB55) obtained from the 
metastatic site of lung adenocarcinoma tissue was cultivated in 1:1 DMEM:F12 medium 
(Invitrogen) supplemented with 10% of fetal bovine serum (FBS), 100 U mL−1 
penicillin, and 100 mg mL−1 streptomycin (Sigma) at 37 °C in 5% CO2. A total of 1 × 
10
6
 cm−2 cells were seeded onto polyethylene terephthalate cell culture inserts 
(Transwell, 1 μm pore size, 12 mm diameter) (BD Bioscience) and were allowed to 
grow and polarize for 7–10 days. The medium was refreshed every second day. 
Monolayers reaching transepithelial electrical resistance (TEER) values around 1200 Ω 
per well, determined using an EVOM TEER meter (World Precision Instruments), were 
considered fully polarized.  
Normal human bronchial epithelial primary cells NHBE (Lonza CC-2540S) isolated 
from epithelial lining of airways above bifurcation of the lungs were differentiated in 
air-liquid interphase (ALI) following the provider’s instructions. Briefly, cells were 
cultivated for 3 days in B-ALI™ growth medium. A total of 1,5 × 105 cm−2 cells were 
seeded onto polyethylene terephthalate cell culture inserts (Transwell, 0,4 μm pore size, 
6,5 mm diameter) (Costar) and were allowed to grow with B-ALI™ growth medium 
both in the basal and apical chamber. After 3 days, B-ALI™ growth medium was 
removed from the apical chamber and complete B-ALI™ differentiation medium was 
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added to the basal chamber and changed every second day for 3-4 weeks until cells 
were completely differentiated.  
CHO-K1 cell line (Chinese hamster ovary cells) (ATCC) was cultured in F12K medium 
(Invitrogen) supplemented with 10% of fetal bovine serum (FBS), 100 U mL−1 
penicillin, and 100 mg mL−1 streptomycin (Sigma) at 37 °C in 5% CO2. Routine 
subcultures were performed at 1:10 split ratios by incubation with 0.05% trypsin-0.02% 
EDTA for 5 min at 37 °C.  
4.4. OMV isolation 
Liquid cultures of BP536 and BP537 were recovered after a 3 days growth in 250 mL 
baffled flasks. The liquid-air volume ratio resulted critical for OMV production yield 
and was kept at 1:5 ratio. Bacteria were then pelleted through centrifugation at 5,000 x g 
for 30 minutes. Cell-free supernatants were recovered and filtered through 0.22 μm 
Stericups filters (Millipore). After ultracentrifugation at 175,000 x g for 2 hours, the 
resulting OMV pellet was washed with Dulbecco's Phosphate-Buffered Saline (D-PBS), 
further ultracentrifuged at 175,000 x g for 2 hours and finally resuspended in 100 µl D-
PBS. OMV were quantified through the Lowry assay (DC Protein Assay, BioRad) for 
total protein content following the manufacturer’s instructions.  
4.5. SDS-PAGE gel analysis 
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis, 
ten micrograms of OMV samples were resuspended in 20 mM Tris-HCl (pH 8.0) buffer 
containing 8% (w/v) SDS and 10 mM DTT, boiled for 5 minutes, separated on 
NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels (Invitrogen) and stained with 
Coomassie Blue R-250.  
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4.6. Nanoparticle tracking analysis 
A NanoSight NS300 instrument (Malvern Ltd) was used to determine OMV particle 
size and concentration as previously described (Olaya-Abril, Prados-Rosales et al. 
2014). Briefly, samples at the protein concentration of 1 µg/μL were diluted 1:500 or 
1:1000 in D-PBS and loaded in the sample chamber. Five videos per samples were 
recorded for 60 seconds and size of individual OMVs and total amount of OMV 
particles were analyzed by Nanoparticle Tracking Analysis 3.2 software (NanoSight 
Ltd.). All measurements were performed at room temperature.  
4.7. Generation of mouse immune sera 
BALB/c mice (10 female/group, 6-week old) (Charles River Laboratories International 
Inc.) received three intraperitoneal immunizations, with a 4 weeks interval, with 
aluminum hydroxide adjuvanted OMV from B. pertussis strain W28 9K/129G (2.5 μg 
per dose) or wP vaccine (NIBSC) at one fifteenth of a human dose. Sera were collected 
before immunization and two weeks after the third immunization. Control mice 
immunized with adjuvant only were included in the experiments. All animal 
experiments were performed in compliance with the Italian law with the approval of the 
local Animal Welfare Body (AWB 2014/06) followed by authorization of Italian 
Ministry of Health. 
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4.8. Adhesion assay 
A549 cell line (Human epithelial alveolar basal adenocarcinoma, ATCC CCL-185) was 
maintained in Ham’s F-12K medium (Life Technologies) supplemented with 10 % (v/v) 
heat-inactivated fetal bovine serum (FBS, Gibco) and antibiotics. Cells were grown at 
37 °C in humidified atmosphere containing 5 % CO2. A549 cells were seeded on black 
96-well plate (2.5x10
4 
cells/ well) and cultured for 1 day in absence of antibiotics.  
For E. coli adhesion assay, bacteria were grown for 16 hours in liquid culture and then 
washed with D-PBS at 8,000 x g for 5 minutes and resuspended at OD600 0.1 in F12-K 
medium. One hundred microliters were transferred in triplicates on plated A549 cells. 
Infected cells were incubated for 3 hours at 37 °C. After extensive washing to remove 
unbound bacteria, cells were fixed with 3.7 % (v/v) formaldehyde (Sigma) for 
20 minutes, blocked with D-PBS containing 3% (w/v) Bovine Serum Albumin (BSA) 
for 15 minutes and incubated with rabbit anti-Escherichia coli polyclonal antibodies 
diluted in D-PBS + 1 % (w/v) BSA (1:500) for 1 hour. After washes, samples were 
incubated with Alexa Fluor® 488 goat anti-rabbit IgG (1:500) (Molecular Probes) for 
30 minutes. After three washes with D-PBS, fluorescence was measured at 
excitation/emission 485/535 nm by Tecan Infinite F200PRO microplate reader. For 
OMV adhesion assay, vesicles were re-suspended in D-PBS to the final concentration of 
10 ng/μL and 100 μL were transferred in triplicates on plated A549 cells. After 6 hours 
of incubation, cells were washed extensively with D-PBS, then fixed with 3.7 % (v/v) 
formaldehyde (Sigma) for 20 minutes, blocked with D-PBS containing 3% (w/v) BSA 
for 15 minutes and incubated with mouse anti-OMV serum diluted in D-PBS  + 1 % 
(w/v) BSA (1:5000) for 1 hour. After washes, samples were incubated with Alexa 
Fluor® 488 rabbit anti-mouse IgG (1:500) (Molecular Probes) for 30 minutes. After 
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three washes with D-PBS, fluorescence was measured at excitation/emission 485/535 
nm by Tecan Infinite F200PRO microplate reader. Adhesion assays were performed 3 
times on different days; statistical analyses were performed using unpaired t test (for B. 
pertussis OMV adhesion) and one-way ANOVA with Dunnett’s multiple comparison 
test (for E. coli adhesion). 
4.9. Adhesion inhibition assay 
For B. pertussis adhesion inhibition assay, bacteria were grown for 16 hours in liquid 
culture and then pelleted at 8,000 ×g for 5 min and resuspended in D-PBS at OD600 0.5. 
A volume of 445 μL of bacterial suspension was then mixed with 50 μL of 1 M 
NaHCO3 and 5 μL of Alexa Fluor® 488 Carboxylic Acid, Succinimidyl Ester 
(Molecular Probes, Life Technologies) and incubated for 15 minutes at 37 °C. After 
centrifugation at 8,000 x g for 5 minutes at room temperature, supernatant was removed 
and pellet was washed once with 1 mL PBS to remove unbound dye and bacteria were 
finally resuspended in F12-K medium at OD600 0.2. Pooled mouse sera were four-fold 
serially diluted in F-12K medium containing 1 % (v/v) naïve mouse serum and pre-
incubated with labeled B. pertussis for 1 hour at 37 °C in 1:1 ratio. One hundred 
microliters of bacteria/serum mixtures were transferred in triplicates on plated A549 
cells. Infected cells were incubated for 1 hour at 37 °C. After extensive washing to 
remove unbound bacteria, fluorescence was measured at excitation/emission 
485/535 nm by Tecan Infinite F200PRO microplate reader. For E. coli adhesion 
inhibition assay, we used the same protocol used for B. pertussis adhesion inhibition 
assay, but we revealed E. coli adhering bacteria by immuno-fluorescence using rabbit 
anti-Escherichia coli polyclonal antibodies as previously described for the adhesion 
assay.  
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4.10. Proteomic analysis by LC-MS/MS, data analysis and 
bioinformatics 
For quantitative proteomic analysis, one hundred micrograms of OMV were TCA 
precipitated as previously described (Tani, Stella et al. 2014) and the protein pellet was 
resuspended in 50 mM ammonium bicarbonate containing 0.1% (w/v) RapiGest SF™ 
(Waters) and 5 mM DTT and heated at 100 °C for 10 minutes. Digestions were 
performed overnight at 37 °C with 2.5 μg trypsin (Promega). Digestions were stopped 
with 0.1% (v/v) final formic acid, desalted using OASIS HLB cartridges (Waters) as 
described by the manufacturer, dried in a Centrivap Concentrator (Labconco) and 
resuspended in 50 μl of 3% (v/v) ACN and 0.1% (v/v) formic acid. Peptide mixtures 
were stored at −20 °C until further analysis. An Acquity HPLC instrument (Waters) was 
coupled on-line to a Q Exactive Plus (Thermo Fisher Scientific) with an electrospray 
ion source (Thermo Fisher Scientific). The peptide mixture (10 μg) was loaded onto a 
C18-reversed phase column Acquity UPLC peptide CSH C18 130Å, 1.7µm 1 x 150 mm 
and separated with a linear gradient of 28–85% buffer B (0.1% (v/v) formic acid in 
ACN) at a flow rate of 50 μL/min and 50 °C. MS data was acquired in positive mode 
using a data-dependent acquisition (DDA) dynamically choosing the five most abundant 
precursor ions from the survey scan (300–1600 m/z) at 70,000 resolution for HCD 
fragmentation. Automatic Gain Control (AGC) was set at 3E
+6
. For MS/MS acquisition, 
the isolation of precursors was performed with a 3 m/z window and MS/MS scans were 
acquired at a resolution of 17,500 at 200 m/z with normalized collision energy of 26 eV.  
Three technical replicates were performed on two biological replicates of OMV purified 
from Bvg+ and Bvg- strains. The mass spectrometric raw data were analyzed with the 
PEAKS software ver. 8 (Bioinformatics Solutions Inc.) for de novo sequencing, 
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database matching identification and label free quantification. Peptide scoring for 
identification was based on a database search with an initial allowed mass deviation of 
the precursor ion of up to 15 ppm. The allowed fragment mass deviation was 0.05 Da. 
Protein identification from MS/MS spectra was performed against B. pertussis Tohama 
I protein database (3,436 protein entries) combined with common contaminants (human 
keratins and autoproteolytic fragments of trypsin) with a FDR set at 0.1%. Enzyme 
specificity was set as C-terminal to Arg and Lys, without allowing cleavage at proline 
bonds and a maximum of four missed cleavages. N-terminal pyroGlu, Met oxidation 
and Gln/Asn deamidation were set as variable modifications. Tryptic digestion from 
rabbit phosphorylase B (Waters) was used as internal standard for label free 
quantification (2 pmol/μL) using a mass tolerance of 20 ppm, a retention time shift 
tolerance of 2 min, minimum 3 different peptides with a FDR set at 0.1%.  
The percentage for each protein in the total samples was subsequently calculated 
multiplying the theoretical molecular weight (MW) of each protein by the average peak 
area and then dividing by the sum of all the average peak areas in each sample, 
multiplied by their theoretical molecular weigth (Average area*MW/Sum(Average 
area*MW)). Percentages were averaged between the two biological samples and finally, 
the fold increase of each protein amount in Bvg+ vs. Bvg- and in Bvg- vs. Bvg+ was 
calculated. A 10-fold increase in amount was set as a threshold for defining Bvg phase 
specificity of each protein.  
PSORTb version 3.0.2 was used for the prediction of protein cellular compartment 
(http://www.psort.org/psortb/) (Nakai and Horton 1999). Further refinement was 
performed for lipoprotein annotation that were sorted from unknown identifications 
using the precompiled genome annotation by DOLOP (http://www.mrc-
lmb.cam.ac.uk/genomes/dolop/) (Madan Babu and Sankaran 2002).  
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4.11. Flow citometry 
E. coli strains were grown for 16 hours in liquid culture. Bacteria were then pelleted and 
washed with D-PBS at 8,000 x g for 5 minutes. Bacteria were then blocked with D-PBS 
containing 3% (w/v) BSA (Sigma) for 15 minutes and incubated with mouse anti-OMV 
serum diluted in D-PBS + 1% (w/v) BSA (1:500) for 1 hour. After washes, samples 
were incubated with Alexa Fluor® 488 goat anti-mouse IgG (1:500) (Molecular Probes) 
for 30 minutes. Finally, bacteria were fixed with 3.7% (v/v) formaldehyde (Sigma) for 
20 minutes and flow cytometry analysis was performed using FACS Canto II flow 
cytometer (BD Biosciences).   
4.12. Recombinant antigen production 
The gene fragment encoding BrkA, corresponding to protein residues 43-726, was 
amplified by PCR from B. pertussis W28 9K/129G genomic DNA. The PCR fragment 
was cloned into the pET15-TEV vector, a modified version of the pET15 vector 
(Novagen), constructed to express N-terminal His-tagged (TEV cleavable) proteins 
(Klock, Koesema et al. 2008). Protein expression was performed in E. coli BL21 (DE3) 
cells, by using EnPresso B growth systems (BioSilta) supplemented with 100 μg/mL 
ampicillin. Bacteria were grown at 30°C for 12 hours, and recombinant protein 
expression was then induced by the addition of 1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) at 25°C for additional 24 hours. Proteins were extracted 
from the insoluble fraction with 6 M of guanidinium chloride and then purified by 
immobilized metal ion affinity chromatography (IMAC) using HiTRAP in 8 M Urea, 
100 mM NaH2PO4 (pH 8) 10 mM Tris HCl (pH 8), 500 mM imidazole (GE Healthcare 
Life Sciences) and refolded by multistep dialysis in 50 mM NaH2PO4 (pH 7.5), 300 mM 
NaCl, 1% (v/v) glycerol.  
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4.13. Mouse aerosol challenge model 
BALB/c mice (10 female/group, 6-week old) (Charles River Laboratories International 
Inc.) received three intraperitoneal immunizations, with a 4 weeks interval, with 
aluminum hydroxide adjuvanted recombinant BrkA (10 μg per dose) or with adjuvant 
only. A bacterial suspension of BP536 from a 24-hour culture was generated at 2 × 10
9 
CFU/mL in D-PBS with 1% (w/v) casein salts (Sigma). BrkA-vaccinated and control 
mice were placed in a closed chamber in which the bacterial suspension was 
administered as an aerosol for 10 min using a nebulizer device with an administration 
rate of 0.5 mL/min. B. pertussis infection was monitored by performing colony forming 
units (CFU) counts on lungs from groups of 10 mice seven days after aerosol challenge. 
Lungs were aseptically removed and homogenized in 2 mL of sterile physiological 
saline buffer with 1% (w/v) casein salts on ice. Ten microliters of undiluted homogenate 
or of serially diluted homogenates were spotted in triplicate onto Bordet-Gengou agar 
plates, and the number of CFU was estimated after three days of incubation at 37°C. 
Statistical analysis was performed using unpaired t test (Mann-Whitney test). 
4.14. Electron microscopy 
B. pertussis strain BP536 was grown for 16 hours at 37°C. An aliquot corresponding to 
OD600=2 was then pelleted, washed with Dulbecco's Phosphate-Buffered Saline (D-
PBS) and re-suspended in 1 mL B-ALI™ growth medium without antibiotics. 100 μL 
were then used to infect NHBE cells grown on transwell inserts. After 1 hour of 
infection, cells were washed with D-PBS to remove unbound bacteria and left in ALI 
for three days before proceeding with the preparation of the samples for electron 
microscopy.  
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Calu-3 cells were incubated with OMV purified from B. pertussis strain BP536 liquid 
cultures, re-suspended in D-PBS at the final concentration of 10 ng/μL. After 6 hour of 
incubation, cells were washed with D-PBS to remove unbound OMV before proceeding 
with the preparation of the samples for electron microscopy.  
Samples were fixed O/N at 4°C in sodium cacodylate buffer 0,1M containing 2,5% 
glutaraldehyde and 2.5% formaldehyde and then post-fixed in 1% OsO4. Samples were 
then dried by the critical point method using CO2 in a Balzers Union CPD 020. For 
SEM samples were sputter-coated with gold in a Balzers MED 010 unit. For TEM, the 
dried samples were embedded in LRWhite resin and stained with uranyl acetate and 
lead citrate. 
4.15. Confocal microscopy 
For immunofluorescence confocal microscopy analysis, A549 cells (4 x 10
4
/well) were 
seeded on 8-well chamber slides (BD BioCoat) and cultured for two days. Cells were 
then incubated with 10 ng/μL of OMV (diluted in F12K + 1% FBS) for 6 hours at 37°C. 
After washing with D-PBS to remove unbound OMV, cells were fixed with 3.7% (v/v) 
formaldehyde (Sigma), permeabilized using Triton 0.25% for 10 minutes at room 
temperature and blocked with D-PBS containing 3% (w/v) BSA for 15 minutes. Cells 
were then incubated with mouse anti-OMV serum diluted in D-PBS + 1 % (w/v) BSA 
(1:5000) for 1 hour. After washes, samples were incubated with Alexa Fluor® 488 
rabbit anti-mouse IgG (1:500) (Molecular Probes) in combination with Alexa Fluor 568 
Phalloidin for 30 minutes. After three washes with D-PBS, glass coverslips were 
mounted with ProLong
® 
reagent with DAPI (Life Technologies) and analyzed using a 
Zeiss LSM710 confocal microscope.  
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4.16. Western Blotting 
OMV were resuspended in SDS-containing sample loading buffer, boiled for 5 minutes, 
separated by SDS-PAGE using the NuPAGE Gel System (Invitrogen) and transferred 
onto nitrocellulose membranes for Western blot analysis. Western blots were performed 
according to standard procedures. FHA and 69K were identified with polyclonal mouse 
antisera raised against the purified proteins (diluted 1:1000). PT subunit 1 (S1) was 
identified with a mouse monoclonal antibody (diluted 1:200). In all cases, an anti-
mouse antiserum conjugated to horseradish peroxidase (Dako) was used as the 
secondary antibody (1:5000). Bands were visualized with Super Signal West Pico 
Chemiluminescent Substrate (Pierce) following the manufacturer’s instructions. 
4.17. PT intoxication assay 
PT toxicity test was performed following the principles described previously (Hewlett, 
Sauer et al. 1983). Two-fold serially diluted OMV from BP536 and W28 PT9K/129G 
(genetically detoxified PT) were mixed with CHO-K1 cells (2x10
5
cells/ml) and 
incubated for 16 hours at 37°C in 96-well plates. PT-mediated toxicity was evaluated by 
observation of morphological alterations (clustered phenotype) by light microscopy. 
Purified PT at 2 ng/ml was used as positive control.  
4.18. Growth assay for iron delivery 
A frozen stock of B. pertussis strain BP536 was inoculated onto BG agar plates. An 
aliquot was taken to inoculate 2 mL of Steiner Sholte medium (supplemented without 
FeSO4) to an initial OD at 600 nm of 0.05. The cultures were incubated at 37°C with 
shaking. FeSO4 or OMV were added at the final concentration of 10 μg/mL and 5 ng/μL 
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respectively. OMV were either purified from B. pertussis cultures in the presence of 
FeSO4 (“loaded OMV”), in the absence of FeSO4 (“empty OMV”), or in the absence of 
FeSO4 and subsequently incubated with FeSO4 (“reloaded OMV”). Cell growth was 
monitored by measuring the OD at 600 nm. Growth assays were performed 3 times on 
different days; statistical analyses were performed using two-way ANOVA with 
Dunnett’s multiple comparison test. 
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